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GASTRORETENTIVE FLOATING MATRIX TABLETS 
OF ATAZANAVIR SULPHATE USING LOW DENSITY 
POLYMERS 
ABSTRACT 
The study was aimed at formulation and evaluation of Fast Disintegrating 
Tablets (FDTs). Using a taste masking polymer Eudragit E100, to mask the taste of a 
delivered drug i.e., Quetiapine Fumarate (QTF). Taste masking was done by solvent 
evaporation technique in absolute Ethanol as solvent system.  Fast Disintegrating 
Tablets of QTF were prepared by using different echniques like Superdisintegrants 
addition method (Croscarmellose sodium (CCS), Sodium starch glycolate (SSG) and 
crospovidone (CP)), sublimation method (Camphor) and Effervescent formulation 
approach (sodiumbicarbonate+citrcacid). All the formulations were evaluated for flow 
properties, hardness, friability, content uniformity, wetting time, in vivo disintegration 
time (DT), release profiles. All the formulations showed satisfactory mechanical 
strength and other formulation parameters within the range. Dissolution parameters 
such as, Initial Dissolution Rate (IDR), Dissolution Efficiency (DE), Mean Dissolution 
Time (MDT) and Relative Dissolution Rate (RDR) were calculated. The optimized 
formula D5 prepared by using 10 % CP as a superdisintegrant and 12 % Camphor as 
subliming agent, which showed shortest DT (17 Sec) ( Q10= 88%, WT= 37Sec). The 
drug polymer complex was subjected to FTIR studies to understand the degree of 
interaction between drug and polymer. The dissolution parameters such as IDR, DE, 
RDR for the optimized formulation exhibited 1.8 fold increase when compared to 
marketed product. It can be concluded that the orally fast disintegrating tablets of QTF 
with better biopharmaceutical properties than conventional marketed tablet obtained 
using formula D5. 
 
 
 
 
ABBREVIATIONS 
 
 
  BP  =  British Pharmacopoeia 
  Conc.   =   Concentration 
  ºC    =  Degree Centigrade 
  F    =   Formulation 
  HCl   =   Hydrochloric acid 
  GRDDS  =   Gastroretentive Drug Delivery System 
  GIT         =   Gastro Intestinal Tract 
  GRT        =   Gastric Retention Time 
  HPMC     =   Hydroxy propyl methyl cellulose 
  h   =   Hour 
  min   =   Minute 
  mL   =   Milliliter 
  N   =   Normality 
  n             =   Diffusion coefficient 
  nm   =   Nanometer 
  rpm        =   Revolution per minute 
  SBC      =   Sodium bicarbonate 
  MCC     =   Micro Crystalline Cellulose 
  BLT      =   Buoyancy Lag Time 
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INTRODUCTION 
            The oral route is the predominant and most preferable route for drug delivery, 
but drug absorption is unsatisfactory and highly variable in the individuals despite 
excellent in vitro release patterns. The major problem is in physiological variability 
such as gastrointestinal transit as well as GRT; the later plays a dominating role in 
overall transit of the dosage forms. GRT of the oral controlled release system is always 
less the 12 h. (pawar et al., 2011,) 
        
            There are numerous drugs that demonstrate poor efficacy and bioavailability 
when administered via the oral route. Such drugs include those that a) act locally within 
the stomach (e.g. amoxicillin), b) are absorbed within the stomach or specific regions of 
the upper intestine (e.g. furosemide), c) are unstable in intestinal fluids (e.g. captopril) 
and d) are poorly soluble within the alkaline environment of the intestine 
(e.g. diazepam). A significant factors leading to the poor bioavailability of numerous 
drugs is due to their narrow absorption window (NAW), most commonly located in the 
upper region of the small intestine i.e. the duodenum and jejunum. These segments of 
the small intestine posses extensive drug absorptive properties and absorption of NAW 
drugs is limited due to the rapid transport of drug past these regions. Therefore this has 
led to researchers exploring the possibilities of extending the gastric residence time 
(GRT) of the drug and therefore indirectly prolonging the time drug is in contact with 
its absorption window for maximal site-specific absorption (Murphy et al.,2009). 
 
One of the most feasible approaches for this in the gastrointestinal tract (GIT) is 
to control GRT using GRDF that will provide us with new and important therapeutic 
options. GRDF are designed on the basis of  one of the several approaches like 
formulating low density dosage form that remain buoyant above the gastric fluid 
(FDDS) or high density dosage form that is retained at the bottom of the stomach, 
imparting bio-adhesion to the stomach mucosa, reducing motility of the GIT by 
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concomitant administration of drugs or pharmaceuticalexicipients, expanding the 
dosage form by swelling or unfolding to a large size which limits the emptying of the 
dosage form through the polymeric sphincter, utilizing ion–exchange resin which 
adheres to mucosa, or using a modified shape system ( Pawar et al. 2011). 
 
GASTROINTESTINAL TRACT PHYSIOLOGY 
 
 The intrinsic properties of the drug molecule and the target environment for 
delivery are the major determining factors in bioavailability of the drug. Factors such as 
pH, enzymes, nature and volume of secretions, residence time, and effective absorbing 
surface area of the site delivery play an important role in drug liberation and absorption. 
 
The stomach is situated in the left upper part of the abdominal cavity 
immediately under the diaphragm. Its size varies according to the amount of distension: 
up to 1500 ml following a meal; after food has emptied, a collapsed state is obtained 
with resting volume of 25–50 ml. 
 
The stomach is anatomically divided into three parts: fundus, body, and antrum 
(or pylorus). The proximal stomach, made up of fundus and body regions, serves as a 
reservoir for the ingested materials, while the distal region (antrum) is the major site of 
mixing motions,  acting as a pump to accomplish gastric emptying( Pawar et al. 2011). 
In stomach there are several types of cells that secrete up to 2–3 liters of gastric juice 
daily. For example, goblet cells secrete mucus, parietal cells secrete hydrochlororic 
acid, and chief cells secrete pepsinogen. The contraction forces of the stomach churn 
the chyme and mix it thoroughly with the gastric juice. The average length of the 
stomach is about 0.2 meter, and the apparent absorbing surface area is about 0.1 m2       
( Talukder and Fassihi et al., 2004). 
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Figure 1. Anatomy of stomach 
Gastric pH 
     
             The gastric pH is not constant rather it is influenced by various factors like diet, 
disease, presence of gases, fatty acids, and other fermentation products ( Rubinstein).In 
addition, the gastric pH exhibits intra-as well as inter-subject variation. This variation in 
pH may significantly influence the performance of orally administered drugs. 
Radiotelemetry, a noninvasive device, has successfully been used to measure the 
gastrointestinal pH in human. It has been reported that the mean value of gastric pH in 
fasted healthy subjects is 1.1±0.15.(lui et al).  On the contrary, the mean gastric pH in 
fed state in healthy males has been reported to be 3.6±0.4, [14] and the pH returns to 
basal level in about 2 to 4 hours. However, in fasted state, basal gastric secretion in 
women is slightly lower than that of in Men (charman et al.,1997). 
 
Gastric pH may be influenced by age, pathological conditions and drugs. About 
20% of the elderly people exhibit either diminished (hypochlorohydria) or no gastric 
acid secretion (achlorohydia) leading to basal pH value over 5.0.(varis et al.,1979) 
Pathological conditions such as pernicious anemia and AIDS may significantly reduce 
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gastric acid secretion leading to elevated gastric pH. In addition, drugs like H2 receptor 
antagonists and proton pump inhibitors significantly reduce gastric acid secretion. 
The pH in the proximal duodenum may rise as high as 4 pH units from the 
stomach.(benn et al., 1971) This increase in pH is caused by the bicarbonate secreted by 
the pancreas and the duodenal mucosa that neutralize the acidic chyme peristalsed from 
the stomach. The mean pH value in fasted duodenum has been reported to be 5.8±0.3 in 
healthy subjects (Mojaverian et al., 1989) while the fasted small intestine has been 
observed to have a mean pH of 6.0±0.14. Passing from jejunum through the mid small 
intestine and ileum, pH rises from about 6.6 to_7.5. 
 
Table 1. Salient features of upper gastrointestinal tract.  
Section 
Length 
(m) 
Transit time 
(h) 
pH 
Microbil 
count(a) 
absorbing 
surface 
area (m2) 
Absorption 
pathways(b) 
Stomach 0.2 Variable       1–4 <103 0.1 P,C,A 
small 
intestine 
6–10 3±1 5–7.5 103–1010 120–200 P,C,A,F.I,E,CM 
Where, 
a - Number of microorganisms per gram of gastrointestinal contents. 
 P, Passive diffusion;  
C, Convective or aqueous channel transport;  
A, Active transport;  
F, Facilitated transport;  
I, ion-pair transport;  
E, entero-or pinocytocis;  
CM, Caveolin mediated transport. 
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Gastrointestinal motility: 
          Two distinct patterns of gastrointestinal motility and secretion exist 
corresponding to the fasted and fed states. As a result the bioavailability of orally 
administered drugs will vary depending on the state of feeding. In the fasted state, it is 
characterized by an inter-digestive series of electrical event and cycle, both through the 
stomach and small intestine every 2–3 h. This activity is called the interdigestive 
myoelectric cycle or Migrating motor complex (MMC). MMC is often divided into four 
consecutive phases: basal (Phase I), pre-burst (Phase II), burst (Phase III), and Phase IV 
intervals. 
 
• Phase I (basal phase) lasts from 40–60 min with rare contractions. 
 
• Phase II (pre-burst phase) lasts for 40–60 min with intermittent action potential and 
contractions. As the phase progresses the intensity and frequency also increases 
gradually. 
 
• Phase III (burst phase) lasts for 4–6 min. It includes intense and regular contractions 
for short periods. Due to this contraction all the undigested material is swept out of the 
stomach down to the small intestine. This is also known as the housekeeper wave. 
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Figure 2.Schematic representation of interdigestive motility pattern. 
 
• Phase IV lasts for 0–5 min and occurs between phases III and I for two consecutive 
cycles. 
The motor activity in the fed state is induced 5–10 min after the ingestion of a meal and 
persists as long as food remains in the stomach. The larger the amount of food ingested, 
the longer the period of fed activity, with usual time spans of 2–6 h, and more typically 
3–4 h, with phasic contractions similar to Phase II of MMC. 
 
Emptying of dosage form from the stomach: 
          
          To achieve gastric retention, the dosage form must resist premature gastric 
emptying. For this, the dosage form must be able to withstand in the stomach against 
the force caused by peristaltic waves. Furthermore, once its purpose has been served the 
dosage form should be removed from the body with ease. Table 2 explains the GIT 
transit time of various dosage forms ( Pawar et al., 2011). 
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Table 2. Transit times of various dosage forms across the GIT. 
Transit time in (h) 
 
Dosage form stomach intestine total 
Tablets 2.7±1.5 3.1±0.4 
5.8 
 
Pellets 1.2±1.3 3.4±14. 
6 
 
Capsules 0.8±1.2 3.2±0.8 
4 
 
Solution 0.3±0.07 4.1±0.5 
4.4 
 
 
Factors Affecting Gastric Retention: 
a)  Density: GRT is a function of dosage form buoyancy that is dependent on the 
density. 
b)  Size: Dosage form units with a diameter of more than 7.5 mm are reported to have 
an increased GRT compared to those with a diameter of 9.9 mm. 
c)  Shape of dosage form: Tetrahedron and ring shaped unfolding expandable GRDF 
with a flexural modulus of 48 and 22.5 kilo pounds per square inch (KSI), respectively, 
are reported to have better GRT ≈ 90–100% retention at 24 h compared with other 
shapes like continuous stick, planar disc, planar multilobe, and string. 
Table 3.polymers used in FDDS. 
d)  Single or multiple unit formulation: Multiple unit formulations show a more 
predictable release profile and insignificant impairing of the performance due to the 
failure of units, allow co-administration of units with different release profiles or 
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containing incompatible substances, and permit a larger margin of safety against dosage 
form failure compared with single unit dosage forms. 
e)  Fed state: Under fasting conditions, the gastrointestinal motility is characterized by 
the periods of strong motor activity or the MMC that occur every 2–3 h. The MMC 
sweeps undigested material from the stomach and, if the timing of administration of 
formulation coincides with that of the MMC, then GRT of the unit may be expected to 
be very short. However, in the fed state, MMC is delayed and GRT is considerably 
longer. 
f)  Nature of meal: Feeding of indigestible polymers or fatty acid salts like cellulose, 
starch, polydextrose, and reffinose can change the motility pattern of the stomach by 
delaying the MMC, thus decreasing the gastric emptying rate and prolonging drug 
release. 
g)  Caloric content: GRT can be increased by 4–10 h with a meal that is high in proteins 
and fats. 
h)  Frequency of feed: The GRT can increase by over 400 min when successive meals 
are given compared with a single meal due to the low frequency of MMC. 
i)  Gender: It was observed that mean GRT in males (3.4 ± 0.6 h) is less than the female 
subjects (4.6 ± 1.2 h) of same age and race. Females emptied their stomach slowly in 
comparison to male candidates, regardless of their weight, height, and body surface 
area. 
j)  Age: Elderly people, especially those over 70, have a significantly longer GRT. 
k)  Posture: GRT can vary between supine and upright ambulatory states of the patient. 
For the floating systems it was reported that when subjects were kept in the upright 
ambulatory position the dosage form stayed continuously on gastric content in 
comparison to the supine state of the patients. Thus, in the upright position of the 
patients floating dosage forms protected against post-prandial emptying. 
l)  Concomitant drug administration: Clonidine, lithium, nicotine, progesterone, anti-
cholinergics like atropine and propantheline, and opiates like codeine prolong GRT. On 
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the other hand, erythromycin and octreotide enhance the gastric emptying. (pawar et 
al.,2011) 
  
MECHANISTIC ATTEMPTS AT GASTRORETENTION 
 
Various polymeric drug delivery systems have been developed that attempt to 
exploit the anatomy and physiology of the GIT environment. These include buoyant 
systems, bioadhesive systems, high density systems, modified shape systems, gastric-
emptying delaying devices and coadministration of gastric-emptying delaying drugs 
(Figure 3). Among these, buoyant drug delivery systems have been used most often. 
 
HIGH DENSITY SYSTEMS 
 
The density of gastric fluid is approximately 1.004g/cm3. Pellets with a density 
of between 2.4-2.8g/cm3 have shown to sink to the bottom of the stomach when a 
patient is in an upright position. The pellets become entrapped within the folds of the 
mucosa thereby withstanding the effects caused by peristalsis (Rouge et al., 1998).  
conducted a comparative study with an immediate release system, a high density system 
and a low density system. The results showed gastric residence times of 0.5, 1 and 2 
hours respectively, indicating that the high density system did not demonstrate any 
significant extension of the gastric residence time.  
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Figure 3.Schematic depicting the classification of gastric retentive systems. 
 
 Excipients which are commonly used in order to increase the density of 
drug delivery systems include: barium sulphate, zinc oxide, iron powder and titanium 
dioxide. Although high density drug delivery systems have not shown remarkable 
significance for the delivery of drugs in a human model, success has been illustrated 
with the administration of pellets with a density of 2.0g/cm3 in the bovine model. 
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Figure 4: Schematic localization of high density system in the stomach. 
 
FLOATING SYSTEMS 
The concept of FDDS was described in literature as early as 1968 (D.W. Davis 
et al), when Davis disclosed a method for overcoming the difficulty experienced by 
some persons of gagging or choking while swallowing medicinal pills. The author 
suggested that such difficulty could be overcome by  providing pills having a density of 
less than 1.0 g/ml so that pill will float on water surface. Since then development of 
FDDS. Several approaches have been used to develop an in ideal 
floating delivery system. 
Based on the mechanism of buoyancy, two distinctly different technologies, i.e., 
noneffervescent andeffervescent systems have been utilized in the development of 
FDDS. The various approaches used in and their mechanisms of buoyancy are 
discussed in the following subsections. 
1.  Noneffervescent FDDS 
The most commonly used excipients in noneffer-vescent FDDS are gel-forming 
or highly swellable cellulose type hydrocolloids, polysaccharides, and matrix forming 
polymers such as polycarbonate, polyacrylate, polymethacrylate and polystyrene. One 
of the approaches to the formulation of such floating dosage forms involves intimate 
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mixing of drug with a gel-forming hydrocolloid, which swells in contact with gastric 
fluid after oral administration and maintains a relative integrity of shape and a bulk 
density of less than unity within the outer gelatinous barrier (Hilton et al., 1992). The air 
trapped by the swollen polymer confers buoyancy to these dosage forms. In addition, 
the gel structure acts as a reservoir for sustained drug release since the drug is slowly 
released by a controlled diffusion through the gelatinous barrier. 
Sheth and Tossounian (Sheth and Tossounian et al., 1978 ) postulated that when 
such dosage forms come in contact with an aqueous medium, the hydrocolloid starts to 
hydrate by first forming a gel at the surface of the dosage form. The resultant gel 
structure then controls the rate of diffusion of solvent-in and drug-out of the dosage 
form. As the exterior surface of the dosage form goes into solution, the gel layer is 
maintained by the immediate adjacent hydrocolloid layer becoming hydrated. As a 
result, the drug dissolves in and diffuses out with the diffusing solvent, creating a 
‘receding boundary. 
 
The various types of this system are as: 
A. Single Layer Floating Tablets: 
 
They are formulated by intimate mixing of drug with a gel-forming hydrocolloid, 
which swells in contact with gastric fluid and maintains bulk density of less than unity. 
They are formulated by intimate mixing of drug with low-density enteric materials such 
as CAP, HPMC. 
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Figure 5.Working principle of the hydrodynamically balanced system (HBS). 
 
B. Bi-layer Floating Tablets: 
A bi-layer tablet contain two layer one immediate release layer which releases 
initial dose from system while the another sustained release layer absorbs gastric fluid, 
forming an impermeable colloidal gel barrier on its surface, and maintain a bulk density 
of less than unity and thereby it remains buoyant in the stomach (Oth et al., 1992). 
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 Figure 6. Intragastric floating bilayer tablet 
 
C.  Alginate Beads: 
Multi-unit floating dosage forms were developed from freeze-dried calcium 
alginate. Spherical beads of approximately 2.5 mm diameter can be prepared by 
dropping sodium alginate solution into aqueous solution of calcium chloride, causing 
precipitation of calcium alginate leading to formation of porous system, which can 
maintain a floating force for over 12 hours. When compared with solid beads, which 
gave a short residence time of 1 hour, and these floating beads gave a prolonged 
residence time of more than 5.5 hours (katayama et al., 1999). 
 
D.  Hollow Microspheres: 
Hollow microspheres (microballoons), loaded with drug in their outer polymer 
shells are prepared by a novel emulsion-solvent diffusion method. The ethanol: 
dichloromethane solution of the drug and an enteric acrylic polymer is poured into an 
agitated aqueous solution of PVA that is thermally controlled at 400C. The gas phase 
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generated in dispersed polymer droplet by evaporation of dichloromethane forms an 
internal cavity in microsphere of polymer with drug. The microballoons float 
continuously over the surface of acidic dissolution media containing surfactant for more 
than 12 hours in vitro (Kawashima, 1992). 
 
2) Effervescent FDDS 
Effervescent systems include use of gas generating agents, carbonates (ex. 
Sodium bicarbonate) and other organic acid (e.g. citric acid and tartaric acid) present in 
the formulation to produce carbon dioxide (CO2) gas, thus reducing the density of the 
system and making it float on the gastric fluid. An alternative is the incorporation of 
matrix containing portion of liquid, which produce gas that evaporates at body 
temperature. 
 
These effervescent systems further classified into two types. 
1. Gas generating systems 
2. Volatile Liquid/Vacuum Containing Systems. 
1.   Gas Generating Systems: 
A. Tablets: 
Floating bilayer tablets with controlled release for furosemide were developed by 
Ozdemir  et al.,  2000.  The  low  solubility  of  the  dru  could be enhanced by using the 
kneading method, preparing a solid dispersion with  β  cyclodextrin mixed in  a 1:1 ratio 
(Singh and Brahma,  2000).  One  layer  contained  the  polymers  HPMC  K4M,  
HPMC K100M and CMC  (for the  control  of the  drug delivery) and the drug. The 
second layer contained theeffervescent mixture of  sodium  bicarbonate  and  citric  
acid.  The  in vitro floating studies revealed that the lesser the compression force the 
shorter is the time of onset of floating, i.e., when the tablets were compressed at 15 
MPa, these could begin to float at 20 minutes whereas at a force of 32 MPa the  time  
was prolonged to 45 minutes. Radiographic  studies  on  6  healthy  male  volunteers  
revealed that floating tablets were retained  in  stomach  for  6  hours  and  further  
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blood  analysis  studies  showed  that bioavailability    of  these  tablets  was  1.8  times  
that  of the  conventional tablets. On measuring the volume of urine the peak diuretic 
effect seen in the conventional tablets was decreased and prolonged in the case of 
floating dosage form.Yang et al., 1999. Developed a swellable asymmetric triple-layer 
tablet with floating ability to prolong the gastric  residence  time   of  triple   drug   
regimen   ( tetracycline,   metronidazole,    and clarithromycin  )     in      Helicobacter 
pylori    –     associated     peptic      ulcers    using hydroxypropylmethyl    cellulose    
(HPMC)     and   polyethylene    oxide  (PEO)  as  the rate-controlling polymeric 
membrane excipients.   The  design of the delivery system was based on the swellable 
asymmetric triple-layer tablet approach. Hydroxypropylmethylcellulose and 
polyethylene oxide were the major rate- controlling polymeric excipients. Tetracycline  
and  metronidazole   were incorporated into the core layer of the triple-layer matrix for 
controlled delivery, while bismuth salt was included in one of the outer layer  for instant  
release 
 
         Figure 7. 
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(a) A multiple-unit oral floating dosage system.(b) stages of floating 
mechanism: (A) penetration of water; (B) generation of CO and floating; (C) dissolution 
of drug. Key: (a) conventional SR pills; (b) effervescent layer; (c) swellable layer; (d) 
expanded swellable membrane layer; (e) surface of water in the beaker (370C). 
          The floatation was accomplished by incorporating a gas-generating layer 
consisting  
of sodium bicarbonate: calcium carbonate (1:2 ratios) along with the polymers. The in 
vitro results revealed that the sustained delivery of tetracycline and metronidazole over 
6 to 8 hours could be achieved while the tablet remained afloat. The floating feature 
aided in prolonging the gastric residence time of this system to maintain high localized 
concentration of tetracycline and metronidazole. 
 
B. Floating capsules: 
Floating capsules are prepared by filling with a mixture of sodium alginate and 
sodium bicarbonate. The systems were shown to float during in vitro tests as a result of 
the generation of CO2 that was trapped in the hydrating gel network on exposure to an 
acidic environment. 
 
C. Multiple unit type floating pills: 
The system consists of sustained release pills as ‘seeds’ surrounded by double 
layers. The inner layer consists of effervescent agents while the outer layer is of 
swellable membrane layer. When the system is immersed in dissolution medium at 
body temp, it sinks at once and then forms swollen pills like balloons, which float as 
they have lower density. This lower density is due to generation and entrapment of CO2 
within the system. 
D. Floating system with Ion-Exchange resins: 
 
A floating system using ion exchange resin that was loaded with bicarbonate by 
mixing the beads with 1M sodium bicarbonate solution (Shweta Arora et al., 2005). The 
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loaded beads were then surrounded by a semipermeable membrane to avoid sudden loss 
of CO2. Upon coming in contact with gastric contents an exchange of chloride and 
bicarbonate ions took place that resulted in CO2 generation thereby carrying beads 
toward the top of gastric contents and producing a floating layer of resin beads. The in 
vivo behavior of the coated and uncoated beads was monitored using a single channel 
analyzing study in 12 healthy human volunteers by gamma radio scintigraphy. Studies 
showed that the gastric residence time was prolonged considerably (24 hours) compared 
with uncoated beads (1 to 3 hours). 
 
 
 
 
Figure 8.Pictorial presentation of working of effervescent floating drug delivery system 
based on ion exchange resin. 
Highly Porous Systems: 
The inclusion of low density polymeric carriers in a formulation may result in a 
matrix with a density of less than 1g/cm3, thereby becoming buoyant. There are 
numerous low density polymeric carriers available, including porous silicon dioxide, 
polypropylene foam, magnesium aluminometa silicate, porous calcium silicate [Jain, 
S.K et al] and polypropylene foam powder [Sher a et al]. These porous carriers possess 
certain characteristics which add to their attractiveness for use in drug delivery systems 
design, including a high surface area, tunable pore sizes with narrow distributions, 
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stable uniform porous structures and well-defined surface properties thus allowing for 
the absorption of drugs and drug release in a reproducible and predictable manner [Sher 
et al., 2007]. 
Hot-Melt Extrusion: 
Hot melt extrusion is a method of continuous mixing and design of moldable 
materials. It is possible to produce tablets, microspheres, granules, transdermal and 
transmucosal delivery systems through this approach [Mididoddi et al., 2007]. 
Polymethacrylate polymers are the most commonly used polymers for this approach 
due to their thermoplastic properties. When selecting a polymer, it is important to 
consider the glass transition temperature, melt viscosity and stability under high 
temperature. Hot-melt extrusion is associated with numerous advantages. These 
advantages include fewer processing steps are involved, the absence of solvents, no 
need for compressionand the thorough mixing of formulation components [Mididoddi et 
al., 2007]. 
2. Volatile Liquid / Vacuum Containing Systems 
A. Intra-gastric floating gastrointestinal drug delivery system: 
These systems can be made to float in the stomach because of floatation 
chamber, which may be a vacuum or filled with air or a harmless gas, while drug 
reservoir is encapsulated inside a micro-porous compartment. 
          
                    
Figure 9.Intra gastric floating gastrointestinal drug delivery device. 
B. Inflatable gastrointestinal delivery systems: 
In these systems an inflatable chamber is incorporated, which contains liquid 
ether that gasifies at body temperature to cause the chamber to inflate in the stomach. 
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These systems are fabricated by loading the inflatable chamber with a drug reservoir, 
which can be a drug impregnated polymeric matrix, encapsulated in a gelatin capsule. 
After oral administration, the capsule dissolves to release the drug reservoir together 
with the inflatable chamber. The inflatable chamber automatically inflates and retains 
the drug reservoir compartment in the stomach. The drug continuously released from 
the reservoir into the gastric fluid. 
 
 
 
 
Figure 10.Inflatable gastrointestinal delivery system. 
 
C. Intragastric osmotically controlled drug delivery system: 
It is comprised of an osmotic pressure controlled drug delivery device and an 
inflatable floating support in a biodegradable capsule. In the stomach, the capsule 
quickly disintegrates to release the intra-gastric osmotically controlled drug delivery 
device. The inflatable support inside forms a deformable hollow polymeric bag that 
contains a liquid that gasifies at body temperature to inflate the bag. The osmotic 
pressure controlled drug delivery device consists of two components; drug reservoir 
compartment and an osmotically active compartment. The drug reservoir compartment 
is enclosed by a pressure responsive collapsible bag, which is impermeable to vapour 
and liquid and has a drug delivery orifice. The osmotically active compartment contains 
an osmotically active salt and is enclosed within a semipermeable housing. In the 
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stomach, the water in the GI fluid is continuously absorbed through the semipermeable 
membrane into osmotically active compartment to dissolve the osmotically active salt. 
The osmotic pressure thus created acts on the collapsible bag and in turn forces the drug 
reservoir compartment to reduce its volume and activate drug release through the 
delivery orifice. 
 
The floating support is also made to contain a bioerodible plug that erodes after 
a predetermined time to deflate the support. The deflated drug delivery system is then 
emptied from the stomach. 
 
 
 
Figure 11.  Intragastric osmotically controlled drug delivery system. 
 
Bioadhesive drug delivery systems: 
Bioadhesive polymers are usually macromolecular, hydrophilic gelling 
substances with numerous hydrogen-bond forming groups, such as carboxyl, hydroxyl, 
amide and sulfate groups (e.g., crosslinked polyacrylic acids, sodium carboxymethyl 
cellulose, sodium alginate and carrageenan). In addition to hydrogen bondings, covalent 
and electrostatic interactions are known to be of importance.  
Although the exact mechanisms of bioadhesion are not yet completely 
understood, certain elements of the process are known to be of significance, such as 
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spreading the bioadhesive over the substrate to increase the surface area of contact; 
diffusion/penetration of polymer chains of the bioadhesive into the substrate; and 
domination of the attractive forces over the repulsive ones. 
Several types of dosage forms have been proposed to allow prolonged residence 
within the stomach based on bioadhesive polymers. For example, (Akiyama and 
Nagahara et al., 1999) developed mucoadhesive microspheres consisting of a drug and 
Carbopol ® 934P  being dispersed within a waxy matrix of polyglycerol esters of fatty 
acids. 
 These systems were reported to adhere to the stomach mucosa in rats and 
Mongolian gerbils, and to prolong the gastrointestinal residence of the drug after oral 
administration. The adherence can probably be explained by the hydration and swelling 
of the Carbopol in the microspheres on contact with water. Importantly, parts of the 
polymer remained within the microspheres, whereas the rest was ‘anchored’ within the 
mucus layer. 
Jackson et al., 2000 observed extended gastric residence times of the positively 
charged ion-exchange resin colestyramine. In addition, this substance had the ability to 
coat the gastric mucosa uniformly. The adherent behaviour was considered to be 
responsible for the prolonged gastric residence. As the oppositely charged ion-exchange 
resin Amberlite IRP-69 did not possess the same characteristics, and as the coating of 
the colestyramine with ethylcellulose (EC) reduced the effects, the surface charge of the 
resin obviously plays a significant role in mucoadhesion and subsequent retention. 
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Figure 12. The two stages involved in muco-adhesion 
 
Expanding Systems 
Expanding drug delivery systems are retained within the stomach due to their 
size that is larger than the diameter of the pyloric sphincter, thereby inhibiting 
its transport into the intestine. When developing an expanding drug delivery system, 
there are a few criteria which should be met. These criteria include:  
 a) The delivery system should be small enough and convenient to swallow, 
 b) It should expand rapidly to an effective size so as to prevent premature 
evacuation from the stomach and  
c) The delivery system should degrade in order to prevent a luminal blockage. 
Expansion of delivery systems is achieved by two mechanisms namely swelling and 
unfolding. Both these mechanisms result in an increase in size which inhibits the 
passage of thedelivery system through the pyloric sphincter into the intestine. Swelling 
occurs due to the absorption of water, usually by osmosis, whereas unfolding occurs 
due to the mechanical shape memory of thepharmaceutical carrier. 
Several geometric shapes, such as tetrahedron, ring, cloverleaf, disk, string and 
pellet/sphere, which can be packed tightly into a gelatin capsule and unfold after 
dissolution of the capsule shell, have been patented by Caldwell et al..  
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These systems consist of at least one erodible polymer (e.g., hydroxypropyl 
cellulose, Eudragit® ), one nonerodible polymer (e.g., polyolefins, polyamides, 
polyurethanes), and a drug that is dispersed within the polymer matrix. The importance 
of the physicalcharacteristics of this type of systems, such as size, shape and flexibility 
on the resulting gastric emptying was studied in beagle dogs (cargill et al., 1988). 
 
Figure 13. Tetrahedron-shaped drug delivery system formed by assembling two 
components: silastic corners and erodible arms. 
 
Super porous  Hydrogels: 
The superporous hydrogel is an expanding system which is currently being 
researched by (Chen et al., 1999). It is due to the unique characteristics associated with 
these superporous hydrogels that they are classified as a new mechanism of gastric 
retention. 
 The superporous hydrogel, when dried, contains open pores which form 
capillary channels. It is due to these open pore channels within the dehydrated hydrogel, 
water is rapidly absorbed, allowing swelling to take place within a few minutes, up to a 
few hundred times its original volume.  
 
 
25 
 
The most unique aspect of the superporous hydrogel is that the average pore size 
is usually in the range of a few hundred micrometers. On hydration, water is taken up 
by capillary wetting as opposed to diffusion. 
 In order to increase the mechanical strength of the hydrogels and to withstand 
peristaltic pressure the superporous hydrogel composites were synthesized by adding 
croscarmellose sodium (Ac-Di- Sol®; FMC Biopolymer).  
Superporous hydrogel can be divided into two groups that are differentiated by 
their swelling ratio and their mechanical stability. is a soft polymer which swells very 
quickly, but has poor mechanical stability, whereas a superporous hydrogel composite 
has a slower swelling rate, but is mechanically stable.  
The composite is therefore utilized as a retentive drug delivery system. Through 
the incorporation of biodegradable crosslinkers, the superporous hydrogel degrades in 
the body thus preventing obstructions within the GIT.  
 
In vivo animal studies demonstrate that the superporous hydrogel remained 
within the stomach for more than 24 hours after feeding. After approximately 30 hours 
there was evidence of fragmentation and the delivery system was cleared from the 
stomach (chen et al., 1999). 
 
 
 
        Figure 14. 
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On the left, superporous hydrogel in its dry (a) and water-swollen (b) state.On the right, 
schematic illustration of the transit of superporous hydrogel. 
Magnetic system: 
These systems appear as small gastroretentive capsules containing a magnetic 
material, whose elimination from the stomach is prevented by the interaction with a 
sufficiently strong magnet applied to the body surface in the region of the stomach. 
Despite numerous reports about successful tests, the real applicability of such systems is 
doubtful because the desired results can be achieved only provided that the 
magnet position is selected with very high precision. Probably, the development of new 
conveniently applied magnetic field sources will improve this concept. 
 
Pharmaceutically or biologically altered gastric emptying: 
Pharmaceutical: 
A rather   simple   method  to  improve  gastric  retention  involves the inclusion 
of either an   excipient  or  pharmaceutical   substance   which   possesses   gastric    
motility retardation   characteristics.    (Stops et  al.,  2006)  investigated  the   use  of 
citric acid to   prolong  the   gastric   residence   time  of  floating  calcium  alginate  
beads.  It  has been proposed that the intake of citric acid decreases duodenal pH to 
below 6, thereby halting gastric motility. A negative feedback system is thus activated 
to restore the pH, allowing re-commence. In vivo studies demonstrated that citric acid 
effectively delayed gastric emptying in the fasted state. 
 
Biological: 
Certain dietary components, such as fats, peptides and some amino acids posses 
the characteristic to prolong gastric emptying and intestinal transit. This phenomenon is 
known as the ileal brake, which is believed to be a feedback process in order to improve 
digestion of dietary components. Components from other biological species have 
been investigated for their ability to delay gastric and intestinal transit. It is known that  
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tapeworms decrease intestinal transit in hosts. For this reason (Kroening et al 2005).  
Investigated the effect of compounds excreted by tapeworms and concluded that cGMP 
is most likely responsible for this delay. It was therefore suggested that the addition of 
cGMP into pharmaceutical formulations may improve drug absorption. 
 
Combinatory Mechanisms Employed For Gastro retention: 
Researchers have recently been investigating the possible advantages of 
combining more than one mechanisms of gastroretention in order to achieve an 
additional enhancement and prolongation of gastric residence time. Visualization is a 
vital step in the development of novel gastroretentive drug delivery systems. Numerous 
approaches have been used in order to explicitly view the positioning and characteristics 
of gastroretentive systems in the GIT. The techniques described hereunder have 
been reported to produce superior results 
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AIM AND OBJECTIVE 
OBJECTIVE 
 
•        Atazanavir sulphate is a highly selective inhibitor of HIV protease and the seventh 
protease inhibitor approved for HIV treatment. Atazanavir is available as 200-, 150- and 
100-mg twice daily capsules. Oral bioavailability of the drug is 69% at fasting state. Its 
t1\2 range from 5-7. As the pH increases the solubility of atazanavir sulphate decreases, 
leading to poor absorption in the intestine. To improve the absorption of atzanavir 
sulphate in stomach and to reduce dosing frequency, atazanavir can be formulated into 
the floating drug delivery system. 
 
•        The present work is aimed at preparing gastric retentive floating matrix tablet 
formulations of Atazanavir sulphate using various low-density polymers. The 
composition of these formulations will be selected by using trial and error methods. 
 
•        To study the effect of various factors like drug polymer ratio, drug sodium 
bicarbonate ratio and polymer grade on the parameters like duration of buoyancy and 
release rate. 
PLAN OF WORK 
 
 To prepare gastric retentive floating tablets of Atazanavir sulphate using   
 different low-density polymers. 
 To select the formulation composition by using trial and error methods. 
 To test all the physical evaluation parameters. 
 To determine floating lag time and total buoyancy time of all the formulations 
 To determine percentage swelling of the formulations. 
 To construct the calibration curve for Atazanavir sulphate 
 To study the release pattern of drug from these formulations using suitable in 
 vitro  model. 
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 Suggest a suitable mechanism of drug release. 
 To select the best formulation based on the above studies. 
  Determination of in vivo gastric retention time of Atazanavir sulphate floating                       
 tablets by using X-ray radiography. 
 Determination of drug-excipients interaction of optimized formulation. 
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LITERATURE SURVEY 
 
Liandong Hu et al., (2011) developed the dextromethorphan hydrobromide 
sustained-release tablets using floating technique to prolong the gastric residence time 
and compared their pharmacokinetic behavior with conventional sustained release 
tablets. DMB-SR floating tablets were prepared employing hydroxypropyl 
methylcellulose (HPMC) as hydrophilic gel material, sodium bicarbonate as gas-
generating agent and hexadecanol as floating assistant agent The floating tablets were 
evaluated for uniformity of weight, hardness, friability, drug content, floating 
characteristics, in vitro release and in vivo bioavailability. The optimized tablets were 
prepared with HPMC K4M 25 mg, sodium bicarbonate 20mg and hexadecanol 18 mg. 
The prepared tablets could float within 3 min and maintain for more than 24 h. The data 
of physical parameters were all lie within the limits. Drug release at 12 h was more than 
85%. The comparative pharmacokinetic study was performed by administration of the 
DMB-SR floating tablets and conventional DMB-SR tablets. 
 
Gangadharappa et al., (2010)develop a controlled release floating 
drug delivery system (tablet) of verapamil hydrochloride. The floating matrix tablets 
were prepared by direct compression technique using a combination of hydroxyl propyl 
methyl cellulose (HPMC) and karaya gum as polymers and sodium bicarbonate as 
generating agent. The prepared floating tablets were evaluated for weight variation test, 
hardness, thickness, swelling index, in vitro floating capabilities, floating lag time, 
compatibility studies, and in vitro drug release. This swellable hydrophilic natural 
karaya gum was used to control the release of drug. The results showed that the 
optimized formulation F8 containing 23.3% of karaya gum (70 mg) and 13.3% of 
HPMC (40 mg) had good floating capability, shorter floating lag time, and sustained 
drug release for the period of 8 h. 
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Jiménez-Martínez et al., (2010) The sustained release of captopril from floating 
matrices has been studied varying the antioxidant load, the sodium bicarbonate 
proportion and the compaction pressure. Although in many cases the effect of 
compaction pressure remains hidden, actual results show that matrices compacted at 55 
MPa have smaller density and float in the dissolution medium while those compacted at 
165 MPa float only adding sodium bicarbonate. The increase of compaction pressure 
reduces the hydration volume and increases the time necessary to attain its maximum. 
These changes are attributed to lower matrix porosity and to the consequent diminution 
of water and drug transport. Increasing ascorbic acid proportions increase the matrix 
hydration volume and the drug released. The use of sodium ascorbate and the 
substitution of 15% polymer with sodium bicarbonate reduce the matrix hydration 
volume, shorten the matrix hydration process and increase the drug released. This is 
attributed to carbon dioxide bubbles that decrease the matrix coherence and expand the 
matrix volume, facilitating drug dissolution and only a limited further matrix expansion. 
 
Bandari et al., (2010) investigated floating sustained-release matrices of 
metoprolol succinate using Gelucire 43/01 and Gelucire 44/14 by a melt-solidification 
technique. The in vitro and in vivo characteristics of the prepared matrices were 
evaluated. The in vitro drug release studies performed in 0.1 N HCl revealed a 
proportional increase in drug release pattern with increased concentration of Gelucire 
44/14. The results indicate that Gelucire 43/01 is an appropriate carrier for the 
development of sustained-release floating drug delivery systems and Gelucire 44/14, a 
highly hydrophilic and lipophilic balance (HLB) excipient, acts as release enhancer in 
the formulations studied. 
 
Bandari S & Yamsani R et al.,(2010)developed a biphasic gastroretentive drug 
delivery system of acyclovir consisted of loading dose tablet and floating multiple 
matrix tablets was prepared by direct compression process. The delivery system was 
designed by hydroxy propyl methyl cellulose as retardant polymer with an effervescent 
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component to get the desired buoyant and sustained release characteristics. All 
formulations compile within the limits. The FTIR studies did not show any evidence of 
an interaction between acyclovir and polymers. Dissolution studies revealed biphasic 
drug release pattern, with loading dose released within 30 min and floating multiple 
matrix tablets provided zero order sustained release profile for 12 h. 
 
Kalpana Swain et al., (2009) investigated controlled release gastroretentive 
floating drug delivery system of theophylline was developed employing response 
surface methodology. A 32 randomized full factorial design was developed to study the 
effect of formulation variables like various viscosity grades and contents of 
hydroxypropyl methylcellulose (HPMC) and their interactions on response variables. 
The floating lag time for all nine experimental trial batches were less than 2 min and 
floatation time of more than 12 h. Theophylline release from the polymeric matrix 
system followed non-Fickian anomalous transport. 
Boldhane & Kuchekar et al., (2009)aimed to develop novel gastroretentive 
(GR) drug delivery system, which releases the drug in the absorption window. As well 
to provide controlled release drug profile that can result patient compliance and 
therapeutic success. Floating tablets of MF was prepared using sodium alginate, and 
sodium carboxymethylcellulose as a gelling agent, and release modifier, respectively. 
Eudragit NE 30 D was used as sustained release polymer to control the initial burst 
release. Drug and excipients compatibility studies were monitored by thermal analysis 
using differential scanning calorimeter. 32 full factorial design was applied to optimize 
the formulation. 
Gutiérrez & Sánchez et al., (2008) Theeffect of sodium bicarbonate (SB) on the 
swelling behavior a3nd the sustained release of floating systems was studied with varied 
proportions of this excipient and  metronidazole. Two polymers with different hydration 
characteristics, Methocel K4M and Carbopol 971P NF, were used to formulate the 
matrices. Under in vitro dissolution conditions, the addition of SB to metronidazole 
sustained-release tablets modifies the matrix hydration volume, increasing at the 
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beginning, reaching a maximum, and then declining. Pure Carbopol matrices show a 
rapid hydration with a limited further effect of the SB and metronidazole loads. 
Methocel show a significant increase of the apparent hydration volume due to SB 
addition with no further notable change due to metronidazole load. Methocel matrices 
release the drug 10% to 15% faster than Carbopol matrices. SB increases the cumulative 
amount of drug released from Methocel but not that releasing from Carbopol. 
Sandra Strübing et al., (2008)Floating Kollidon® SR matrix tablets containing 
Propranolol HCl were developed and characterized with respect to drug release 
characteristics and floating strength. Kollidon® SR was able to delay Propranolol HCl 
release efficiently. Drug release kinetics was evaluated using the Korsmeyer– Peppas 
model and found to be governed by Fickian diffusion. Tablet floating started 
immediately and continued for 24 h. Floating strength was related to Kollidon® SR 
level with  improved floating characteristics for samples with a high polymer/drug 
ratio.  The influence of the polymer content on swelling characteristics was found to be 
only marginal. Furthermore, the new method of benchtop MRI was introduced to study 
the water diffusion and swelling behaviour non-invasively and continuously. 
Mastiholimath et al., (2008)delivered an anti-ulcer drug, ranitidine 
hydrochloride through a gastroretentive ethyl cellulosebased microparticulate system 
capable of floating on simulated gastric fluid for  12 h. Preparation of microparticles is 
done by solvent evaporation technique with modification by using an ethanol co-solvent 
system. The formulated microspheres were free flowing with good packability and 
encapsulation efficiencies were up to 96%.The data obtained thus suggests that a 
microparticulate floating delivery system can be successfully designed to give 
controlled drug delivery, improved oral bioavailability and many other desirable 
characteristics. 
Lingam  Meka et al., (2008)developed a gastro retentive floating drug delivery 
system with multiple-unit minitablets based on gas formation technique for furosemide. 
The system consists of core units (solid dispersion of furosemide:povidone and other 
excipients), prepared by direct compression process, which are coated with two 
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successive layers, one of which is an effervescent (sodium bicarbonate) layer and other 
one an outer polymeric layer of polymethacrylatesOnly the system using Eudragit 
RL30D and combination of them as polymeric layer could float within acceptable time. 
The time to float decreased as amount of the effervescent agent increased and, when the 
coating level of polymeric layer decreased. The drug release was controlled and linear 
with the square root of time. By increasing coating level of polymeric layer decreased 
the drug release. The in vivo gastric residence time was examined by radiograms and it 
was observed that the units remained in the stomach for about 6 h. 
Gupta & Pathak et al., (2008)optimizeed floating microballoons of famotidine 
by the emulsion solvent diffusion technique using central composite design. 
Formulations F1–F15 were prepared using three independent variables (pH of medium, 
drug: Eudragit® S100 ratio and ethanol : dichloromethane ratio) and evaluated for 
dependent variables (shape, percentage buoyancy, and encapsulation). The optimized 
formulation F9 was fractionated and a polymer combination of (Eudragit® S100 : 
Eudragit® L100-55, 9.5:0.5) resulted in microballoons that exhibited zero order release 
(94.73%) with 84.20% buoyancy at the end of the eighth hour when studied in the 
mesh-designed modified USP type II apparatus. 
Singh et al., (2007) developed of floating matrix tablets of metoclopramide 
hydrochloride (MHCl) for improving its bioavailability by prolonging gastric residence 
time. Floating matrix tablets (FMT) of MHCl were prepared using the polymers guar 
gum (GG), karaya gum (KG), HPMC E15 (HE) alone and in combination with HPMC 
K15M (HK) and gas generating agents such as calcium carbonate and citric acid. The 
fabricated tablets were evaluated for their physical characteristics such as hardness, 
drug content, buoyancy, swelling properties and in vitro release studies in 0.1N HCl. 
Jaimini et al., (2007)prepared a gastroretentive drug delivery system of 
famotidine. Floating tablets of famotidine were prepared employing two different 
grades of methocel K100 and methocel K15M by effervescent technique. The floating 
tablets were evaluated for uniformity of weight, hardness, friability, drug content, in 
vitro buoyancy and dissolution studies. The effect of citric acid on drug release profile 
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and floating properties was investigated. The prepared tablets exhibited satisfactory 
physico-chemical characteristics. All the prepared batches showed good in vitro 
buoyancy. The tablet swelled radially and axially during in vitro buoyancy studies. It 
was observed that the tablet remained buoyant for 6-10 hours. Decrease in the citric 
acid level increased the floating lag time but tablets floated for longer duration. A 
combination of sodium bicarbonate (130mg) and citric acid (10mg) was found to 
achieve optimum in vitro buoyancy. The tablets with methocel K100 were found to 
float for longer duration as compared with formulations containing methocel K15M. 
The drug release from the tablets was sufficiently sustained and non-Fickian transport 
of the drug from tablets was confirmed. 
Patel et al.,(2007)developed a gastroretentive drug delivery system of 
carbamazepine using HPMC, sodium bicarbonate, and EC as matrixing agent, gas-
generating agent, and floating enhancer, respectively. A simplex lattice design was 
applied to investigate the combined effect of 3 formulation variables (ie, amount of 
HPMC (X 1), EC (X 2), and sodium bicarbonate (X 3). Results of multiple regression 
analysis indicated that low levels ofX 1 andX 2 and a high level  ofX3 should be used to 
manufacture the tablet formulation with desired in vitro floating time and dissolution. 
Cedillo & Ramírez et al.,(2006) In vitro dissolution of metronidazole from 
sustained release floating tablets was studied with varied proportions of sodium 
bicarbonate (SB) and Pharmatose DCL 11. Two polymers with different hydration 
characteristics, Methocel K4M and Carbopol 971P NF, were used to formulate the 
matrices. The variables studied include the matrices’ release profile, hydration volume, 
and floating behavior. All Methocel matrices floated more than 8 h with SB proportions 
up to 24%, while Carbopol matrices floated more than 8 h with SB proportions only up 
to 12%.Methocel matrices showed greater hydration volumes and greater drug 
dissolution compared to Carbopol matrices. After adding increasing quantities of 
Pharmatose to matrices containing 12% SB, hydration volume decreased while 
dissolution increased. 
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Srivastava et al., (2005)developed floating matrix tablets of atenolol to prolong 
gastric residence time and increase drug bioavailability. Atenolol was chosen as a 
model drug because it is poorly absorbed from the lower gastrointestinal tract. The 
tablets were prepared by direct compression technique, using polymers such as 
hydroxypropyl methylcellulose (HPMC K15M, K4M), guargum (GG), and sodium 
carboxymethylcellulose (SCMC), alone or in combination, and other standard 
excipients. Tablets were evaluated for physical characteristics viz. hardness, swelling 
index, floating capacity, thickness, and weight variation. Further, tablets were evaluated 
for in vitro release characteristics for 8 hr. The effect of effervescent on buoyancy and 
drug release pattern was also studied. 
Bhaskar Chauhan et al., (2005)prepared Single and multi-unit floating matrices 
of risedronate sodium  using Gelucire1 43/01 by melt solidification and melt 
granulation technique, respectively. The controlled release floating matrices were 
evaluated for in vitro and in vivo floating ability and in vitro drug release. Effect of 
aging on Gelucire1 43/01 was evaluated by hot stage microscopy (HSM), scanning 
electron microscopy (SEM), differential scanning calorimetry (DSC), in vitro floating 
ability, and in vitro drug release. Multi-unit system obtained has shown initial burst 
release, which was suppressed in single unitsystem. Both single- as well as multi-unit 
systems showed increase in rate of drug release on aging due to changes in the 
properties of the Gelucire1 43/01. 
Anant Paradkar et al., (2004) explored the application of Gelucire 43/01 for the 
design of multi-unit floating systems of a highly water-soluble drug diltiazem HCl. 
Diltiazem HCl-Gelucire 43/01 granules were prepared by melt granulation technique. 
The granules were evaluated for in vitro and in vivo floating ability, surface 
topography, and in vitro drug release. Aging effect on storage was evaluated using 
scanning electron microscopy, hot stage polarizing microscopy (HSPM), differential 
scanning calorimetry (DSC), and in vitro drug release. Granules were retained in 
stomach at least for 6 hours. Approximately 65% to 80% drug was released over 6 
hours with initial fast release from the surface. 
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Moursy et al., (2003) developed sustained release floating capsules of 
nicardipine HCl. For floating, hydrocolloids of high viscosity grades were used and to 
aid in buoyancy sodium  bicarbonate was added to allow evolution of CO2. In vitro 
analysis of a commercially available 20-mg capsule of nicardipine HCl (MICARD) was 
performed for comparison. Results showed an increase in floating with increase in 
proportion of hydrocolloid. Inclusion of sodium bicarbonate increased buoyancy. The 
optimized sustained release floating capsule formulation was evaluated in vivo and 
compared with MICARD capsules using rabbits at a dose equivalent to a human dose of 
40 mg. Drug duration after the administration of sustained release capsules significantly 
exceeded that of the MICARD capsules. In the latter case the drug was traced for 8 
hours compared with 16 hours in former case. 
 
Yie W. Chien et al., (2002) evaluated  the contribution of formulation variables 
on the floating properties of a gastric floating drug delivery system (GFDDS) using a 
continuous floating monitoring system and statistical experimental design. Several 
formulation variables, such as different types of hydroxypropyl methylcellulose 
(HPMC), varying HPMC/Carbopol ratio, and addition of magnesium stearate, were 
evaluated using Taguchi design, and the effects of these variables were subjected to 
statistical analysis. It was found that the HPMC of higher viscosity grade generally 
exhibited a greater floating capacity, but the effect was not statistically significant. For 
polymers with the same viscosity, i.e., K4M and E4M, the degree of substitution of the 
function group did not show any significant contribution. A better floating behavior was 
achieved at higher HPMC/Carbopol ratio. Carbopol appeared to have a negative effect 
on the floating behavior of GFDDS. 
Talwar et al., (2001) developed a once-daily formulation for oral administration 
of ciprofloxacin. The formulation was composed of 69.9% ciprofloxacin base, 0.34% 
sodium alginate, 1.03% xanthum gum, 13.7% sodium bicarbonate, and 12.1% cross-
linked poly vinyl pyrrolidine. The viscolysing agent initially and the gel-forming 
polymer later formed a hydrated gel matrix that entrapped the gas, causing the tablet to 
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float and be retained in the stomach or upper part of the small intestine (spatial control). 
The hydrated gel matrix created a tortuous diffusion path for the drug, resulting in 
sustained release of the. 
 
Sasa Baumgartner et al., (2000)development of the floating matrix tablets, 
which after oral administration are designed to prolong the gastric residence time, 
increase the drug bioavailability and diminish the side effects of irritating drugs. Tablets 
containing hydroxypropyl methylcellulose (HPMC), drug and different additives were 
compressed. The investigation shows that tablet composition and mechanical strength 
have the greatest influence on the floating properties and drug release. With the 
incorporation of a gas-generating agent together with microcrystalline cellulose, besides 
optimum floating (floating lag time, 30 s; duration of floating, >8 h), the drug content 
was also increased. The drug release from those tablets was sufficiently sustained (more 
than 8 h) and non-Fickian transport of the drug from tablets was confirmed. 
Krogel and Bodmeier., (1999)developed and evaluated floating drug delivery 
system based on effervescent core and a polymeric coating. The mechanical properties 
(puncture strength and elongation) of acrylic (Eudragit RS, RL and NE) and cellulose 
(cellulose acetate, ethyl cellulose) polymer, which primarily determined the type of 
delivery system, a polymer coating with a high elongation value and high water low 
carbon dioxide permeability was selected (Eudragit RL/ acetyl tributyl citrate 20%w/w) 
in order to initiate the effervescent reaction and the floating process rapidly. HPMC was 
also added in the core to retard drug release. The composition and hardness of the tablet 
core and the composition and hardness of the coating could control the time of flotation. 
Chen and Hao., (1998)studied the in vitro performance of floating sustained 
release capsule of verapamil. Capsules filled with mixture of verapamil, HPC and 
effervescent materials are proposed to provide floating and sustained release for over 10 
hrs. The effects of weight filled in the capsule, amount of HPC and the addition of 
effervescent material on the dissolution kinetics were studied. They concluded that the 
 
 
39 
 
release of Verapamil from the capsule followed Higuchi release model. However, when 
effervescent material was added, the system showed a zero-order release. 
Doelkar et al., (1996) have showed the effect of film forming polymers on 
floating behavior of   coated floating formulations.  Films plasticized with water- 
soluble plasticizers are more permeable for aqueous medium but should rupture earlier 
than films prepared with water insoluble plasticizers. Cellulose  acetate, mechanically 
strong polymer, is too rigid and do not expand  to  large  extent  when  comes  in  
contact  with dissolution  medium. Ethyl polymers mechanically weak polymer, it is not 
flexible and easily ruptures upon   CO2   formation; acrylic polymers are more suitable 
for the FDDS. The floatation time decreases with increasing Eudragit RL content  in 
Eudragit  RS/RL  coating and was  longer  with  coatings  containing  acetyl  tributyl 
citrate (ATBC)  as plasticizer  than with coating containing triethyl citrate (TEC). 
Jimenez et al., (1994)designed and tested the in vitro floating and bioadhesive 
property of Sotalol for oral application. Tablets were prepared by mixing the active 
ingredient with Sodiumcarboxymethylcellulose, hydroxy propylcellulose and a 
carbonate to generate gas. In vitro tests for release of drug, floatation and bioadhesion 
of the tablets were carried out. They concluded that this system showed good 
characteristics for controlled drug delivery system. 
 
DRUG PROFILE 
Non Proprietary Name: Atazanavir Sulphate   
Proprietary name         :   Latazanavir, Reyataz, Zrivada 
Chemical name            :  methyl N-[(1S)-1-{N'-[(2S,3S)-2-hydroxy-3-[(2S)-2-    
                                        (methoxycarbonyl)amino]-3,3-dimethylbutanamido]-4- 
                                        phenylbutyl]-N'-{[4-(pyridin-2-yl) phenyl] methyl} 
       hydrazinecarbonyl} -2,2dimethylpropyl] carbamate. 
Empirical formula       :  C38H52N6O7 
Molecular weight :  704.856 g/mol 
Structure  : 
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Physicochemical Properties:  
 
Description: 
 Atazanavir Sulphate White to pale yellow crystalline powder . 
Solubility:  
Freely soluble in water and methanol. 
Pharmaceutical Profile: 
            Dosage Forms and dose: 100mg, 150mg, 200mg, 300mg capsules. 
Pharmacopoeial status: 
 United States Pharmacopoeia 
Analytical Profile: 
            Spectrophotometry: Spectrophotometric determination of Atazanavir Sulphate in 
methanol with the λmax at 301nm has been reported. 
 
PHARMACOKINETIC PROFILE 
Oral absorption: 60-68%. 
Plasma half life: 5-7 hours. 
Protein binding: 86 % 
 
PHARMACOLOGICAL PROFILE 
Therapeutical category: Anti HIV. 
Mechanism of action: Atazanavir selectively inhibits the virus-specific processing of 
viral Gag and Gag-Pol polyproteins in HIV-1 infected cells by binding to the active site 
of HIV-1 protease, thus preventing the formation of mature virions. Atazanavir is not 
active against HIV-2.   
Therapeutic/clinical uses: Used in combination with other antiretroviral agents for the 
treatment of HIV-1 infection, as well as post exposure prophylaxis of HIV infection in 
individuals who have had occupational or nonoccupational exposure to potentially 
 
 
42 
 
infectious body fluids of a person known to be infected with HIV when that exposure 
represents a substantial risk for HIV transmission. 
Adverse effects:  
Bilirubin levels in the blood are normally asymptomatically raised with 
atazanavir. A single case of torsades de pointes attributable to atazanavir therapy has 
been described. 
Contraindication: 
 Atazanavir should not be used with proton pump inhibitors, such as omeprazole 
(Prilosec), esomeprazole (Nexium), or rabeprazole (Aciphex). According to the FDA, 
"A 76% reduction in atazanavir area under the concentration-time curve (AUC) and a 
78% reduction in atazanavir trough plasma concentration (Cmin) were observed when 
REYATAZ/ritonavir [a protease inhibitor, the same class as Atazanavir] 300/100 mg 
was co administered with omeprazole 40 mg." In other words, proton pump inhibitors 
reduce the effects of atazanavir.  
 
HYDROXYPROPYLMETHYLCELLULOSE (HPMC)     (SS) 
Nomenclature 
Non-proprietary names 
•        JP        : Hydroxypropylmethylcellulose 
•        BP       : Hypromellose 
•        Ph Eur :  Methylhydroxypropylcellulosum 
•        USP     :  Hypromellose 
Chemical Name:  Cellulose hydroxypropyl methyl ether 
Synonyms: Benecel MHPC; E464; hydroxypropyl methylcellulose; HPMC; 
hypromellosum; Methocel; methylcellulose propylene glycol ether; methyl 
hydroxypropylcellulose; Metolose; MHPC; Pharmacoat; Tylopur; Tylose MO. 
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Structural Formula: 
 
Where R is H, CH3, or CH3CH(OH)CH2 
Physical and chemical properties: 
* Molecular weight: 10,000 - 15, 00,000 
* Color: White to creamy-white 
* Nature: Fibrous or granular powder 
* Odour: Odourless 
* Taste: Tasteless 
* Density: 0.3-1.3 g/ml 
* Specific gravity:  
             1.26* Solubility: Soluble in cold water, practically insoluble in Chloroform, 
ethanol (95%) and ether but Soluble in mixture of ethanol and Dichloromethane. 
* Viscosity: HPMC K100LV:   80-120 mPas 
     HPMC-K4M:  2663–4970 
     HPMC K15M: 14 000-16 000 
    HPMC K100M:  72,750–135,800 
* Melting point:  
Browns at 190-200 ºC, chars at 225-230 ºC, Glass transition temperature is 170-
180ºC. 
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Functional Category 
          Coating agent, film-forming, rate-controlling polymer for sustained release, 
stabilizing  agent, suspending agent, tablet binder, viscosity-increasing agent. 
 
Application 
• In oral product HPMC is primarily used as tablet binder, in film coating and as an 
extended release tablet matrix. Concentration between 2-5% w/w may be used as a 
binder in either wet or dry granulation process. High viscosity grade may be used to 
retard the release of water-soluble drug from a matrix. 
• HPMC is widely used in oral and topical pharmaceutical formulation. 
• Concentration of 0.45-1% w/w may be added as a thickening agent to vehicle for eye 
drop and artificial tear solution. 
• HPMC is used as an adhesive in plastic bandage and as a wetting agent for hard 
contact lenses. It is widely used in cosmetics and food products. 
• In addition, HPMC is used as an emulsifier, suspending agent and stabilizing agent in 
topical gels and ointments. As a protective colloid, it can prevent droplets and particle 
from coalescing or agglomerating thus, inhibiting the formation of sediments. 
Stability and storage 
         It is stable although it is slightly hygroscopic. The bulk material should be stored 
in an airtight container in a cool and dry place. Increased in temperature reduces the 
viscosity of the solution. 
Safety 
         It is generally regarded as a non-toxic and non-irritant material so it is widely used 
in many oral and topical pharmaceutical formulations. Excessive consumption of 
HPMC may have laxative effect. 
 
SODIUM BICARBONATE 
Nomenclature 
Non-proprietary names 
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 JP: Sodium bicarbonate                                     
 BP: Sodium bicarbonate 
 Ph Eur :   Natrii hydrogencarbonas  
 USP:  Sodium bicarbonate 
Chemical Name: Carbonic acid monosodium salt 
Molecular weight: 84.01 
Structural Formula: NaHCO 
 
Physical and chemical properties 
Colour: White  
Nature: Crystalline powder 
Odour: Odourless 
Taste: Saline/slight alkaline 
Density: 0.869-2.173 g/cm3 
Moisture content: less than 1%w/w 
Solubility: Soluble in water, practically insoluble in ethanol (95%) and ether. 
Osmolarity:  1.39% w/v aqueous solution is isoosmotic with serum. 
Melting point: 270 ºC (with decomposition) 
 
Functional category 
Alkalizing agent, therapeutic agent. 
 
Applications 
 Used in pharmaceutical formulation as a source of carbon dioxide in 
 effervescent      tablets and granules. 
 Used to produce or maintain an alkaline pH in a preparation, like solution of 
 Erythromycin, Lidocaine, and Niacin etc. 
 Used to produce a sodium salt of the active ingredient that has enhanced 
 solubility. 
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 Used as a freeze-drying stabilizer and in toothpaste. 
 Used as a gas forming agent in alginate raft system and in floating drug delivery 
 system. 
 
Stability and Storage 
          Sodium bicarbonate is stable in dry air but slowly decomposed in moist air and 
should therefore be store in well-closed container in a cool dry place. 
 
Safety 
        Orally ingested sodium bicarbonate neutralizes gastric acid with the evolution of 
carbon dioxide and may cause stomach cramps and flatulence (Rowe et al., 2003). 
 
LACTOSE ANHYDROUS: 
Nonproprietary Names: 
 BP: Anhydrous Lactose 
 JP: Anhydrous Lactose 
 PhEur: Lactose, Anhydrous 
 USP-NF: Anhydrous Lactose 
Synonyms: Anhydrous 60M; Anhydrous Direct Tableting (DT); Anhydrous DT High 
Velocity; Anhydrous Impalpable; Lactopress Anhydrous; Lactopress Anhydrous 250; 
lactosum anhydricum; lattosio; milk sugar; SuperTab 21AN; SuperTab 22AN; 
saccharum lactis. 
Chemical Name: O-b-D-Galactopyranosyl-(1!4)-b-D-glucopyranose 
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Structural Formula: 
 
 
Description: 
 
          Anhydrous lactose occurs as white to off-white crystalline particles or powder. 
Several different brands of anhydrous lactose are commercially available which contain 
anhydrous b-lactose and anhydrous a-lactose. Anhydrous lactose typically contains 70–
80% anhydrous b-lactose and 20–30% anhydrous a-lactose. 
Functional Category:  
 
Directly compressible tablet excipient; dry powder inhaler carrier; lyophilization 
aid; tablet and capsule diluents; tablet and capsule filler.     
 
Applications in Pharmaceutical Formulation or Technology: 
            Anhydrous lactose is widely used in direct compression tableting applications, 
and as a tablet and capsule filler and binder. Anhydrous lactose can be used with 
moisture-sensitive drugs due to its low moisture content. It may also be used in 
intravenous injections. 
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Stability and Storage Conditions: 
 
Mold growth may occur under humid conditions (80% RH and above). Lactose 
may  develop  a  brown  coloration  on  storage, the reaction being accelerated by warm, 
damp conditions. Lactose anhydrous should be stored in a well-
closed container in a cool, dry place. 
Safety: 
 
Adverse reactions to lactose are largely due to lactose intolerance, which occurs 
in individuals with a deficiency of the intestinal enzyme lactase, and is associated with 
oral ingestion of amounts well over those found in solid dosage forms. 
 
MAGNESIUM STEARATE: 
            Magnesium Stearate is a very fine, light white, precipitated or milled, 
impalpable powder of low bulk density,  having  a  faint odor of stearic acid and a 
characteristic taste. The  powder  is  greasy  to  the  touch  and readily adheres to the 
skin. It is widely used in cosmetics,  foods,  and  pharmaceutical formulations. It is 
primarily used as a lubricant in capsule and tablet manufacture at concentrations 
between 0.25% and 5.0% w/w. It is also used  in  barrier  creams.  It  is  practically  
insoluble  in ethanol, ethanol (95%), ether and water; slightly soluble in warm benzene 
and warm ethanol (95%). Magnesium Stearate is officially available in IP, BP, and 
USP. 
TALC: 
            It  is  very  fine,  white  to  grayish -white,  odorless,  impalpable    and   
unctuous crystalline   powder.  Powder is soft to  touch and readily adhere to the skin 
and free from grittiness. It is used as anti caking agent,    tablet   and    capsule   diluents   
and tablet and capsule lubricant. It is insoluble in dilute acids,   alkalis,  organic  
solvents and   water. It is stable  and  should  be stored in a well-closed container, in a 
cool and dry place. Talc is officially available in IP, BP, and USP. 
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METHODOLOGY 
 
Standard graph of Atazanavir sulphate: 
Principle:  
The calibration curve is based on the spectrophotometry. The maximum 
absorption was observed at 301nm. It obeyed Beer’s law in the concentration range of 
5-40µg/ml. 
 
Method: 
Standard stock solution: 
        The stock solutions was freshly prepared by dissolving 100mg of atazanavir 
sulphate in a 100ml volumetric flask and then make up the solution upto the mark using 
0.1N HCl  for obtaining the solution of strength 1000 µg/mL (stock I). 10ml of 
this solution is diluted to 100ml with 0.1N HCl to obtain a solution of strength 100 
µg/mL (stock II). From this secondary stock required concentrations 
5,10,15,20,25,30,35 and 40µg/mL was prepared. The absorbance was measured at 301 
nm using a UV spectrophotometer (Systronic, Ahmedabad, India). Standard 
calibration curve values were shown in Table (7). 
Preparation of Atazanavir sulphate floating matrix tablets: 
Tablets containing Atazanavir sulphate were prepared by direct compression 
method. The respective powders drug, polymers(HPMC K4M, HPMC K 15M, HPMC 
K100M), sodium bicarbonate(20%), lactose were blended thoroughly with mortar and 
pestle. The powder blend was then lubricated with magnesium stearate and talc mixed 
for about 3 minutes. The required amount of the blend was weighed and finally this 
mixture was compressed on a 16-station rotary tablet machine (Cadmach, Ahmedabad, 
India) using a 10-mm standard flat-face punches. 
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Table 5.  Formula for Preparing Floating Matrix Tablets of Atazanavir sulphate: 
S.No Formulation Atazanavir sulphate 
HPMC 
K4M 
HPMC 
K15M 
HPMC 
K100 
M 
SBC Lactose Talc Mg Stearate 
1 F1 150 52.5   70 70.5 3.5 3.5 
2 F2 150 42   70 81 3.5 3.5 
3 F3 150 28   70 95 3.5 3.5 
4 F4 150 28   80 85 3.5 3.5 
5 F5 150 28   90 75 3.5 3.5 
6 F6 150 21   70 102 3.5 3.5 
7 F7 150 21   80 92 3.5 3.5 
8 F8 150 21   90 82 3.5 3.5 
9 F9 150 14   70 109 3.5 3.5 
10 F10 150  52.5  70 70.5 3.5 3.5 
11 F11 150  42  70 81 3.5 3.5 
12 F12 150  28  70 95 3.5 3.5 
13 F13 150  21  70 102 3.5 3.5 
14 F14 150  14  70 109 3.5 3.5 
15 F15 150   42 70 81 3.5 3.5 
16 F16 150   28 70 95 3.5 3.5 
17 F17 150   21 70 102 3.5 3.5 
18 F18 150   14 70 109 3.5 3.5 
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Where, 
Drug= Atazanavir sulphate;  
HPMC= Hydroxypropylmethylcellulose; 
SBC=sodium bicarbonate;  
MCC= Microcrystalline cellulose. 
Lactose and MCC was used as filler in formulations F1 to F19. 
All the numerical values were expressed in mg. 
 
EVALUATION OF TABLETS: 
 
Evaluation was performed to assess the physicochemical properties and release 
characteristics of the developed formulations. Following parameters were evaluated. 
Tablet thickness: 
           The thickness in millimeters (mm) was measured individually for 10 pre weighed 
tablets by using vernier calipers. The average thickness and standard deviation were 
reported. 
Weight variation: 
          Twenty (20) tablets from each batch were individually weighed in grams (gm) on 
an analytical balance. The average weight and standard deviation were calculated and 
the results were expressed as compliance or non-compliance of set limits.   
        
Average weight (mg) % Deviation allowed 
130 or less 10 
130-323 7.5 
More than 324 5 
 
Table 6.Weight variation tolerance 
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Hardness of the tablets: 
          Ten tablets were measured in the hardness examination. Tablet hardness was 
measured using a Monsanto hardness tester. The crushing strength of the 10 tablets with 
known weight and thickness of each was recorded in kg/cm2 and the average hardness 
and standard deviation was reported. 
Friability of the tablets: 
          Twenty tablets of the formulation were weighed and measured in a Roche type 
friabilator. The tablets were rotated at 25rpm for 4min, and the samples were then 
reweighed. The percentage friability was calculated using the equation. 
 
F % = ( W1-W2)/W1 X 100 
   F% represents the percentage weight loss, and W1 and W2 are the 
initial and   final tablets weights, respectively. 
Content uniformity: 
            Ten tablets were weighed and triturated to get fine powder. Weight equivalent to 
10 mg of Atazanavir sulphate was dissolved in 10 ml of 0.1 N HCl and agitated for 15 
min, the volume was adjusted to 100 ml using 0.1 N HCl with continuous agitation for 
5min. The solution was filtered and suitable dilutions were prepared with 0.1 N HCl. 
Same concentration of the standard solution was also prepared. The drug content was 
estimated by recording the absorbance at 301nm by using UV-
Visible spectrophotometer. 
 
The floating lag time and the total floating time: 
       This test was characterized by floating lag time and total floating time. The test was 
performed using USP XXIII type II paddle apparatus using 900 ml of 0.1 N HCl at 
paddle rotation of 50 rpm at 37 ± 0.5o C. The time required for tablet to rise to surface 
of dissolution medium and duration of time the tablet constantly float on dissolution 
medium was noted as floating lag time and total floating time 
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Water uptake studies: 
The swelling behavior of dosage unit can be measured either by studying its 
dimensional changes, weight gain or water uptake. The water uptake study of the 
dosage  form was conducted by using USP dissolutionapparatus-II in a 900ml of 
distilled water which was maintained at 37o + 0.5oc, rotated at 50 rpm. At 
selectedregular intervals the tablet was withdrawn and weighed. Percentage swelling of 
the tablet was expressed aspercentage water uptake (%WU) (Chavanpatil et al.,2006). 
 
                %Water Uptake   = (Wt - Wo) * 100 / Wo 
Where,  
Wt - is the weight of the swollen tablet and    
Wo - is the initial weight of the tablet. 
 
Drug–excipients interaction studies: 
In order to evaluate the integrity and compatibility of the drug in the 
formulation, drug–excipient interaction studies were performed. The infrared spectra of 
pure drug, physical mixture of drug and excipients, polymer and formulation were 
recorded between 4000 to 400 cm-1on FTIR. The IR spectra for the test samples were 
obtained using KBr disk method using an FTIR spectrometer. 
Dissolution Study of tablets: 
Apparatus: Dissolution test apparatus (USP XXIII) 
Method: USP type 2 apparatus (paddle method) 
Dissolution medium: 0.1N HCl 
Volume: 900 ml 
Temperature: 37 + 0.5 ºC 
Speed: 50 rpm 
 The tablet was placed inside the dissolution vessel. 5ml of sample were 
withdrawn at time intervals of 0.5, 1, 2, 3, 4, 6, 8, 10 and 12h. The volume of 
dissolution fluid adjusted to 900 ml by replacing 5ml of dissolution medium after each 
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sampling. The release studies were conducted with 3 tablets, & the mean values were 
plotted versus time. Each sample was analyzed at 301 nm using double beam UV and 
Visible Spectrophotometer against reagent blank. 
Thedrug concentration was calculated using standard calibration curve. 
 
Mechanism of drug release: 
         The different mathematical models may be applied for describing the kinetics of 
the drug release process from tablets; the most suited being the one which best fits to 
the experimental results. 
The kinetics of Atazanavir sulphate release from tablets formulations were 
determined by finding the best fit of the release data to zero order, first order, matrix, 
Hixson-Crowell, Higuchi, and Korsmeyer-Peppas plots. Zero order release rate kinetics. 
To study the zero–order release kinetics the release rate data are fitted to the following 
equation. 
F= Ko.t 
Where ‘F’ is the drug release,  
‘K’ is the release rate constant and  
‘t’ is the release time. 
The plot of % drug release versus time is linear. First order release rate kinetics. The 
release rate data are fitted to the following equation 
                  Log (100-F) = kt 
     A plot of log % drug release versus time is linear. 
Higuchi release model: 
According to this model, drug release was described as a square root of time-
dependent diffusion process based on Fick’s law. 
Qt = KH  t1/2 
where KH is Higuchi’s rate constant, and Qt is the amount of drug released at time t. 
If a plot of square root of time vs cumulative amount of drug released yields a straight 
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line, then the particular dosage form is considered to follow Higuchi kinetics of drug 
release 
 
Korsmeyer and Peppas release model: 
 
Under some experimental situations the release mechanism deviates from  the 
Fick’s equation, following an anomalous behavior (Non-Fickian release). In these cases 
a more generic equation can be used. Korsmeyer et al. (23) developed a simple, semi-
empirical, relating exponentially the drug release to the lapsed time. 
 
Qt /Q∞ = K.tn 
Where, Qt /Q∞ is the fraction of drug released, 
‘K’ is the release constant,  
‘t’ is the release time,  
‘n’ is diffusion exponent if n is equal to 0.89, the release is zero order. If n is equal to 
0.45 the release is best explained by Fickian diffusion, and if 0.45 < n < 0.89 then the 
release is through anomalous diffusion or nonfickian diffusion (Swellable & Cylindrical 
Matrix).In this model, a plot of log (Qt/Q∞) versus log (time) is linear. 
 
In vivo confirmation of buoyancy by using radiographic studies: 
For this study the tablets were prepared by replacing half of the amount of drug 
with barium sulfate. After overnight fasting of three healthy volunteers they were fed 
with low calorie food and allowed to take water after these tablets were administered 
orally.  Radiographs were obtained at 0.5, 1, 2, 3, 4 and 6 h. Over these periods 
volunteers were allowed to take water. 
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RESULTS AND DISCUSSION 
STANDARD GRAPH 
 
Table 7. Standard Curve values of Atazanavir sulphate at 301nm 
 
Concentration Absorbance 
0 0 
5 0.096 
10 0.178 
15 0.247 
20 0.314 
25 0.384 
30 0.443 
35 0.514 
40 0.58 
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Figure 15.Standard Curve values of Atazanavir sulphate at 301nm 
The study started with the construction of standard calibration curve of 
Atazanavir sulphate.The lmax of Atazanavir sulphate in 0.1N HCl was scanned and found 
to have the maximum absorbance at 301 nm. Standard graph of Atazanavir sulphate in 
0.1N HCl was plotted by taking concentration ranging from 5 to 40 µg/mL and a good 
correlation was obtained with R2 value of 0.996. 
The fabricated matrix tablets of Atazanavir sulphate were evaluated for their 
physical characteristics such as weight variation, hardness, thickness, friability, drug 
content, buoyancy. The possibility of drug excipients interaction was determined with 
the help of and FTIR. 
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Table 8.Physical evaluation parameters 
Formulacod
e 
Weight 
variation(
mg) 
Hardness 
kg/cm2 
Thickness 
(mm) 
Friabil
ity 
(%) 
Lag 
time 
(sec) 
Total 
floati
ng 
time 
(h) 
Drug 
Content 
(%) 
F1 347±2.3 4±0.5 3.21±0.08 0.26 118 >12 
97.32±2.
3 
F2 351±3.8 4±0.5 3.23±0.06 0.23 148 >12 
98.56±2.
0 
F3 356±4.5 4±0.3 3.21±0.06 0.48 290 >12 
98.21±1.
8 
F4 351±8.3 4±0.5 3.22±0.09 0.51 85 >12 
95.91±1.
5 
F5 345±5.3 4±0.2 3.26±0.08 0.22 54 6 
97.75±2.
3 
F6 349±2.3 4±0.5 3.21±0.05 0.41 >300 6 
96.25±1.
8 
F7 353±5.5 4±0.5 3.24±0.05 0.35 139 6 
97.48±2.
8 
F8 344±5.6 4±0.2 3.28±0.02 0.38 103 4 
97.69±2.
4 
F9 348±3.3 4±0.5 3.23±0.02 0.41       - - 
97.35±1.
7 
F10 346±6.2 4±0.3 3.21±0.16 0.29 98 >12 
96.55±2.
4 
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F11 351±4.3 4±0.5 3.28±0.05 0.38 103 >12 
94.48±1.
8 
F12 349±2.3 4±0.4 3.19±0.09 0.41 112 >12 
95.42±.0
9 
F13 345±2.9 4±0.5 3.29±0.05 0.52 169 >12 
95.99±1.
3 
F14 348±8.3 4±0.5 3.26±0.02 0.34 - - 
98.91±2.
8 
F15 353±3.8 4±0.4 3.23±0.02 0.45 52 >12 
98.46±3.
2 
F16 346±4.9 4±0.3 3.27±0.02 0.25 67 >12 
97.41±2.
1 
F17 349±8.3 4±0.1 3.23±0.02 0.28 79 >12 
97.97±2.
6 
F18 347±6.33 4±0.7 3.28±0.02 0.38 >200 6 
98.91±2.
8 
 
Weight variation data of the prepared tablets indicated no significant difference 
in the weight of individualtablet from the average value. The weight variations of the 
tablets were within the permissible limits of 5%, as specified for tablet weighing more 
than 324mg (Table 8). Weight of the tablet was fixed at 350 mg and the weight 
variation for every batch was tested and found within the acceptance limits 
Hardness of the tablet was fixed 4 kg/cm2 and was maintained for all the batches 
in order to minimize the effect of hardness on the drug release because, the effect of 
polymer concentration is the only area of interest. 
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Tablet thickness was also used to assess the quality of tablets. Under uniform 
conditions of manufacture, the total weight of tablet and thickness were linearly related. 
The thickness of floating tablets ranged from 3.19 to 3.29 mm and linearly correlated 
with the weight of the tablets (Table 8). Friability test of all the formulations was found 
satisfactory showing enough resistance to the mechanical shock and abrasion. Drug 
content uniformity in all formulations was calculated and the percent of active 
ingredient ranged from 95-98% (Table 8). 
Floating capacity of fabricated tablets was determined in 0.1N HCl, and 
the results are presented in Table 8. Sodium bicarbonate was added as a gas-generating 
agent. TheCO2 generated by effervescent gets entrapped in the gel layer and helps the 
tablets become buoyant in less time. However, incorporation of larger amounts 
of effervescent may cause quicker depletion of tablet matrices (Deshpande et al., 1996; 
Hwang et al., 1998) with an expected decrease in floating duration. 
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Figure 16.In vitrobuoyancy study of Atazanavir sulphate floating tablets 
All the batches showed good in vitro buoyancy. The results of 
the invitro buoyancy study of atazanavir sulphate tablets are shown in Figure 19. The 
figure clearly indicates the floating lag time (2 min) of the atazanavir sulphate tablet and 
swelling tendency of the formulation.Hydroxypropylmethylcellulose (HPMC) K4M, 
HPMC K15M, K100M was evaluated varying the sodium bicarbonate portion 
70,80,90mg per tablet.When the concentration of sodium bicarbonate was 70 mg/tablet, 
the tablets could not float immediately. When amount of sodium bicarbonate was 
increased above 90 mg, the tablets could not retain its physical integrity for more than 
6h.Finally, lag time was observed less than 2 min for all the formulations and then 
optimizing the sodium bicarbonate portion at 80mg per tablet(22.8%w/w) to the total 
tablet weight. 
The results of percentage swelling obtained from the water uptake studies of the 
formulations containing HPMC K4M were shown in table 9 and 10.  The formulations 
with HPMC K4M , HPMC K15M and HPMC K100M showed the swelling and tablet 
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integrity (Figure 16-18). Maximum swelling was observed for formulations with HPMC 
K4M, HPMC K 15M and HPMC K100M at the end of 6h, then after wards no increase 
in the water uptake was observed. The formulation F1 containing K4M (15 %w/w that 
of tablet weight) shows the higher swelling compared to that of the formulations 
containing K15M (12.5% w/w that of total tablet weight). 
As HPMC K15M and HPMC K100M are high viscosity polymers there is an 
increase in water uptake with less percent of polymer in comparison with same ratio. 
The swelling index of the tablets increases with an increase in the polymer viscosity 
grades as shown in figure 17to 19. 
 
Table 9.Percent swelling of formulations with HPMC K4M 
 
Time(H)        F1           F2        F3     F4       F5 
1 16.97±0.30 14.05±0.69 14.87±0.94 13.87±0.28 13.62±0.86 
2 22.47±0.02 21.25±0.38 22.73±0.92 25.01±0.10 23.54±0.31 
3 48.34±0.31 47.60±0.66 35.68±0.53 38.21±0.33 35.27±0.15 
4 69.19±0.66 60.67±0.82 55.39±0.35 50.08±0.66 53.13±0.35 
6 80.83±0.33 74.51±0.33 67.33±0.71 69.86±0.66 60.32±1.18 
8 75.59±0.66 71.97±0.98 64.69±0.53 66.87±0.98 21.91±0.15 
10 71.20±0.66 71.17±1.02 63.93±0.88 65.28±0.50  
12 70.99±0.82 66.78±0.33 57.29±0.53 59.94±0.83  
 
Data represents mean ± SD (n=3) 
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Figure 17- Percentage swelling of HPMC K4M Vs Time 
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Table 10.Percent swelling of formulations with HPMC K15M 
     
Time(H)        F10           F11        F12    F13       F14 
1 16.97±0.30 14.05±0.69 14.87±0.94 13.87±0.28 10.62±0.86 
2 22.47±0.02 21.25±0.38 19.73±0.92 18.01±0.10 15.54±0.31 
3 48.34±0.31 47.60±0.66 44.68±0.53 38.21±0.33 20.27±0.15 
4 69.19±0.66 60.67±0.82 58.39±0.35 56.08±0.66 31.13±0.35 
6 81.83±0.33 74.51±0.33 70.33±0.71 65.86±0.66 45.32±1.18 
8 79.59±0.66 72.97±0.98 68.69±0.53 62.87±0.98  
10 76.20±0.66 68.17±1.02 66.93±0.88 61.28±0.50  
12 70.99±0.82 64.78±0.33 60.29±0.53 57.94±0.83  
 
                 Data represents mean ± SD (n=3) 
 
 
                       Figure 18- Percentage swelling of HPMC K15M Vs Time 
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Table 11.Percent swelling of formulations with HPMC K100M 
Time(h) F15 F16 F17 F18 
1 25±0.65 21.50±0.34 18.33±0.90 10.62±0.86 
2 36.24±0.34 31.17±0.87 22.17±0.67 15.54±0.31 
3 69.50±0.98 64.67±0.71 59.67±1.45 20.27±0.15 
4 87.00±0.78 78.17±0.61 66.50±1.56 39.13±0.35 
6 96.50±0.65 84.67±0.85 72.83±0.34 48.32±1.18 
8 80.17±2.34 76.67±1.45 68.00±0.67 51.91±0.15 
10 76.83±0.92 74.50±0.64 68.33±0.81  
12 70.50±1.32 64.50±0.78 62.33±0.64  
               Data represents mean ± SD (n=3) 
 
 
Figure 19- Percentage swelling of HPMC K100M Vs Time. 
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The in vitro dissolution testing was performed and the results of the 
formulations were expressed in tables 12, 13, 14 and 15. 
 
The release of Atazanavir sulphate was studied using USP 
dissolution apparatus II. The dissolution media were 900 ml 0.1 N HCl maintained at 37 
± 0.50C with rotation speed of 50 rpm. Aliquots of 5 ml was collected at predetermined 
time intervals and replenished with equivalent volume of fresh medium. The samples 
were diluted to a suitable concentration with 0.1N HCl and were analyzed by using 
UV/VIS double beam spectrophotometer at 301nm.The results are expressed as 
mean±S.D (n=3). 
 
In vitro dissolution study of formulations F1, F2, F3 , F4 and F5 were done in 
0.1 N HCl and the Percent of drug release from formulations F1, F2, F3, F4 and F5 was 
61.79, 69.85, 82.43, 89.43 and 94.07 in 12 hours respectively. F1, F2, F3, F4 
formulations floated for 12 h. All this formulations contain a lower viscosity grade 
polymer compared with that of other two polymers.The release rate was faster with 
lower viscosity grades of HPMC, probably owing to less polymer entanglement and less 
gel strength and also to the larger effective molecular diffusion area at lower viscosity 
as compared with higher viscosity grades of HPMC. Moreover, the tablets formed by 
the higher viscosity grade HPMC would have more gel strength than the one formed by 
the lower viscosity grade because of which, the erosion would be less. 
 
As the concentration of the polymer decreased from F1 to F3 the drug release 
was increased. It is increased from 61.79 to 82.43 from F1 to F3 respectively. The 
differences in the release may be due to the amount of gel layer formed on the surface 
of the tablets. HPMC K4M at higher concentrations results in a greater amount of gel 
being formed. This gel increases diffusion length so that drug release was decreased. 
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The formulations F3,F4 and F5 are formulated by varying the concentrations of 
sodium bicarbonate. When the concentration of sodium bicarbonate was 70 mg/tablet, 
the tablets could not float immediately. This might be due to the gas generated was not 
sufficient to keep the formulation float immediately. When amount of sodium 
bicarbonate was increased above 90 mg, the tablets could not retain its physical 
integrity for 6 h. when the sodium bicarbonate concentration was 80 mg(F4) the tablet 
float immediately and release was good. 
                   Table 12:Percent drug release of formulations with HPMC K4M 
 
Time(h)        F1           F2        F3    F4       F5 
1 5.4±0.30 6.51±0.69 11.28±0.94 9.3±0.28 9.08±0.86 
2 10.92±0.02 10.56±0.38 20.96±0.92 13.97±0.10 14.48±0.31 
4 17.82±0.66 13.45±0.82 44.82±0.35 21.77±0.66 22.75±0.35 
6 22.41±0.33 21.08±0.33 58.81±0.71 40.5±0.66 43.28±1.18 
8 39.21±0.66 42.42±0.98 68.87±0.53 61.71±0.98 69.42±0.15 
10 50.35±0.66 51±1.02 76.96±0.88 78.43±0.50 85.92±0.35 
12 61.71±0.82 69.85±0.33 82.43±0.53 89.43±0.83 94.07±1.18 
                  Data represents mean ± SD (n=3) 
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     Figure 20- Percent drug release of HPMC K4M Vs Time. 
 
Further test is carried out by decreasing the polymer concentration further in 
order to increase the drug release. Formulations F6, F7, and F9 are prepared but the 
floating tablets could not retain its physical integrity for desired period of time. If its 
physical integrity could not be maintained, tablet would be broken down into smaller 
fragments and escape from the upper part of the gastrointestinal tract. At higher sodium 
bicarbonate concentrations F8 showed good release. 
The in vitro dissolution studies for the formulations F10, F11, F12, F13 and F14 
prepared with HPMC K15M were done in 0.1N HCl and the percent of drug release 
from formulation F10, F11, F12, F13 was 51.29, 55.97, 74.05, 78.96 in 12 hours 
respectively (Figure 8). As the concentration of the polymer is decreased the amount of 
drug release increases. Among these the formulation F13 has shown maximum drug 
release in 12 hours with floating lag time of 169 seconds. 
The in vitro dissolution studies for the formulations F15, F16, F17 and F18 
prepared with HPMC K100M were done in 0.1N HCl and the percent of drug release 
from formulation  F15, F16, F17 was 43.3, 51.25, 69.46 in 12 hours respectively 
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(Figure 9). Formulations floated for 12 h. As the concentration of the polymer is 
decreasedthe amount of drug release increases. 
     Table 13: Percent drug release of formulations with HPMC K4M 
 
Time(H)        F6           F7        F8    F9 
1 38.14±0.20 7.2±0.96 11.01±0.49 44.34±0.81 
2 56.35±0.80 26.57±0.36 16.28±0.92 57.85±0.10 
4 70.78±0.61 49.9±0.84 25.15±0.33 83.5±0.67 
6 82±0.39 68.14±0.34 52.28±0.77 85.5±0.63 
8 89.35±0.67 76.9±0.99 71.78±0.53 94.7±0.97 
10 90±0.69 89.35±1.02 94.71±0.88 96.87±0.50 
11 94.07±0.86 94.5±0.33 92.71±0.53 94.07±0.89 
                Data represents mean ± SD (n=3) 
 
 
Figure 21-Percent drug release of HPMC K4M Vs Time. 
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Table 14:Percent drug release of formulations with HPMC K15M 
 
 
                      Data represents mean ± SD (n=3) 
 
       
 
                   Figure 22-Percent drug release of HPMC K15M Vs Time. 
 
Time (h) F10 F11 F12 F13 F14 
1 4.05±0.01 6.64±0.17 9.05±0.45 9.77±0.78 32.77±0.25 
2 5.59±0.15 10.77±0.41 12.40±0.46 16.28±0.33 38.48±0.69 
4 11.62±2.56 13.73±0.03 22.65±0.30 33.85±0.39 71.68±5.34 
6 15.76±0.79 19.61±0.61 37.78±0.65 46.92±0.62 85.64±0.62 
8 19.37±3.54 28.09±0.77   53.53±0.70  55.92±0.70 90.29±0.70 
10 36.32±0.91 38.26±2.15 64.72±2.5  68.67±2.5    94.10±2.5 
12 51.29±1.23 55.97±0.61 74.05±0.78 78.96±0.78 93.67±0.78 
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            Table 15 .Percent drug release of formulations with HPMC K100M 
Time (h)      F15 F16 F17 F18 
1 4.3±1.19 6.29±0.66 6.51±0.84 31.70±0.25 
2 5.73±0.03 9.16±0.71 11.0±0.61 44.95±0.69 
4 9.23±7.57 10.64±1.30 17.64±0.31 72.53±5.34 
6 11.39±2.30 13.94±1.40 33.00±0.78 84.04±0.62 
8 14.84±0.53 17.41±1.40 45.51±1.09 86.67±0.70 
10 24.37±1.69 29.53±2.02 59.53±1.09 92.08±2.5 
12 43.3±0.30 51.25±0.27 69.46±0.78      94.69±0.78 
 
                    Data represents mean ± SD (n=3) 
 
 
Figure 23-Percent drug release of HPMC K100M Vs Time. 
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The regression coefficient (R2) values of release data of all formulations 
obtained by curve fitting method for zeroorder, first-order, and Higuchi and Krosmeyer-
Peppas model are reported in Table 16. Most of the formulations follow the zero order 
and Higuchi model. For the optimized formulation F4, the R2 value of zero order 0.985 
(nearer to 1) is dominant than the other models. 
The mechanism of drug release is predicted by using according to Krosmeyer–
Peppas. The n value of optimized formulation F4 is 0.832. This indicates that the drug 
release mechanism is of non-fickian diffusion. The R2 value of F4 formulation for Zero-
order is near to 1 which indicated the drug release mechanism is of zero-order resulting 
from constant surface area and controlled swelling/ erosion provided by the changing 
geometry of the system. 
 
Table 16: Release kinetics of optimized formulations  
 
Formulation 
Zero 
order 
First order Higuchi 
Korsmeyer 
& Peppas 
Peppas(n) 
F4 0.985 0.957 0.940 0.842 0.832 
F1 0.991 0.943 0.963 0.941 0.807 
 
To get evidence of possible chemical interaction of drug with the excipients, 
FTIR analysis was used . Figure xxx shows the IR spectra of Atazanavir sulphate , 
HPMC K4M , and the F3 formulation. Pure drug shows a characteristic peak at 
1699.29, 1674.21, 1651.07 cm-1 that is due to C=O stretching of ketonic group and 
3261.63, 3215.34 cm-1 are due to N-H stretching. HPMC K4M show important bands at 
1456.26 and 1417.68 cm-1, respectively. The FTIR spectrum of the optimized 
formulation displays the characteristic peaks of both drug and HPMC K4M. Overall, 
there was no alteration in the characteristic peaks of drug and HPMC K4M 
suggesting that there was no interaction between the drug and HPMC K4M. 
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Figure 24.Ftir Results of Atazanavir, polymer And Tablet Composition. 
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SUMMARY 
 
 Gastroretentive floating matrix tablets of Atazanavir sulphate were successfully 
prepared with hydrophilic polymers like HPMC K4M, HPMC K15M.,HPMC 
100M. 
  The formulated batches were evaluated for physicochemical parameters, 
floating properties and dissolution profiles. From the evaluation results it was 
observed that the tablets contain the higher viscosity HPMC showed long 
floating lag time when compared to tablets prepared with lower viscosity 
HPMC. The physical properties like hardness, weight variation and friability of 
majority of the batches complied with the pharmacopoeial specifications. The 
drug content of all tablets was in the range of 95 – 100%. 
 In vitro dissolution study of all the formulations were done in 0.1 N HCl The 
release rate was faster with lower viscosity grades of HPMC, probably owing to 
less polymer entanglement and less gel strength and also to the larger effective 
molecular diffusion area at lower viscosity as compared with higher viscosity 
grades of HPMC. 
 
 The regression coefficient (R2) values of release data of all formulations 
obtained by curve fitting method for zero-order, first-order, and Higuchi and 
Krosmeyer-Peppas model. 
 For the optimized formulation F4, the R2 value of Zero order is 0.985 (nearer to 
1) is dominant than the other models which indicates that the drug release 
follows zero order. The n value of optimized formulation F4 is 0.832. This 
indicates that the drug release mechanism is of non-fickian diffusion. 
 FTIR studies showed there was no interaction between drug and polymer. 
 The in- vivo X-ray studies, conducted in the healthy human volunteers, it was 
found that the gastric retention time was 6 hours. 
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CONCLUSION 
 
The Atazanavir sulphate  floating tablets were successfully prepared. The 
addition of gel-forming polymer HPMC (K4M) and gas-generating agent sodium 
bicarbonate  were provided  the buoyancy and drug release. The prepared tablets could 
float within 3min and maintain for more than 12 h. The drug release at 12 h was more 
than 85%. The uniformity of weight, hardness, friability, drug content were all lying 
within the limits. The FTIR results showed there was no exipient interactions. Finally 
In-vivo studies showed that the tablet was retained in stomach for 6 hours. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
76 
 
REFERENCES 
 
1. Akiyama Y, Nagahara N: Novel formulation approaches to oral mucoadhesive drug 
delivery systems.In: Bioadhesive Drug Delivery Systems –Fundamentals, Novel 
Approaches and Development. E Mathiowitz,DE Chickering III, CM Lehr 
(Eds.),Marcel Dekker, New York, NY, USA (1999):477-505. 
 
2. Benn, A.; Cooke, W.T. Intraluminal pH ofduodenum and jejunum in fasting subjects 
with normal and abnormal gastric or pancreatic function.Scand. J. Gastroenterol. 
(1971), 6, 313–317. 
 
3.Bhaskar C, Shyam S,  Mahadik K R, and Anant P Preparation and Evaluation of 
Floating Risedronate Sodium–Gelucire1 43/01 Formulations Drug Development and 
Industrial Pharmacy, (2005) 31:851–860. 
 
4. Caldwell us Patents MERCK AND CO.: EP0202159 (1986). 
 
5. Cargill R, Caldwell LJ, Engle K, Fix JA, Porter PA, Gardner CR. Controlled gastric 
emptying. Effects of physical properties on gastric residence times of non disintegrating 
geometric shapes in beagle dogs.Pharm. Res. (1988) 5:533-536. 
6.Cedillo-Ramírez E and Villafuerte-Robles L, Hernández-León A. Industrial 
Pharmacy, Vol. 32, No. 8, July 2006: pp. 1–43 Effect of Added Pharmatose DCL11 on 
the Sustained-Release of Metronidazole From Methocel K4M and Carbopol 971P NF 
Floating Matrices Drug Development and Industrial Pharmacy, (2006) 32:955–965. 
 
7. Charman, W.N.; Porter, J.H.; Mithani, S.; Dressman,J.B. Physicochemical and 
physiological mechanisms for the effects of food on drug absorption:the role of lipids 
and pH. J. Pharm. Sci. (1997), 86 (3), 269–282. 
 
 
77 
 
8. Chen J, Park H, Park K: Synthesis of superporous hydrogels: hydrogels with fast 
swelling and superabsorbent properties.J Biomed Mater Res (1999), 44:53-62. 
9. Dasharath M. Patel, Natvarlal M. Patel, Nitesh N. Pandya, and Pranav D. Jogani 
Gastroretentive Drug Delivery System of Carbamazepine: Formulation Optimization 
Using Simplex Lattice Design: A Technical Note. AAPS PharmSciTech (2007); 8 (1) 
Article 11. 
 
10. Davis D W. Method of swallowing a pill, US Patent 3, 418,29 (1984) 513–519. 
 
11. Gangadharappa H V,  Rahamath-Ulla M,  Pramod-Kumar T M, and  Shakeel F.  
Floating drug delivery system of verapamil hydrochloride using karaya gum and 
HPMC. 
 
12. Gan-Lin C and Wei-Hua H. In Vitro Performance of Floating Sustained-Release 
Capsule of Verapamil Drug Development and Industrial Pharmacy, (1998) 24(1), 1067-
1072. 
 
13. Hao Z, Xuetao J, Lingshan K, Shen G. Design and Evaluation of a Dry Coated Drug 
Delivery System With Floating–Pulsatile Release.Journal of Pharmaceutical Sciences, 
(2008) Vol. 97, 263–273. 
 
14. Hilton A.K, Deasy P.B. In vitro and in vivo evaluation of an oral sustained-release 
floating dosage form of amoxycillintrihydrate. Int. J. Pharm. 86 (1992) 79–88. 
 
15. Ina K, Roland B .Floating or pulsatile drug delivery systems based on coated 
effervescent cores International Journal of Pharmaceutics 187 (1999) 175–184. 
 
 
 
 
78 
 
16. Inéz Jiménez M, Adriana Miriam Domínguez R, and Leopoldo Villafuerte R.  
Effect of antioxidants on captopril floating matrices Pharmaceutical Development and 
Technology,(2010);15(3):230–240. 
17. Jackson SJ, Bush D, Washington N, Perkins AC. Effect of resin surface charge on 
gastric mucoadhesion and residence of cholestyramine.Int. J. Pharm. (2000) 205:173-18 
 
18. Jaimini, A.C. Rana and Y.S. Tanwar Formulation and Evaluation of Famotidine 
Floating Tablets.Current Drug Delivery, 2007, 4, 51-55. 
 
19. Jain, S.K.; Awasthi, A.M.; Jain, N.K.; Agrawal, G.P. Calcium silicate based 
microspheres of repaglinide for gastro retentive floating drug delivery: Preparation and 
vitro characterization. J. Control. Release, (2005), 107, 300-309. 
 
20. Kalpana S, Satyanarayan P, Subrata M, and Korla Appana C. Influence of 
hydroxypropyl methylcellulose on drug release pattern of a gastroretentive floating drug 
delivery system using a 32 full factorial design Pharmaceutical Development and 
Technology,(2009); 14(2): 193–198. 
 
21. Katayama H, Nishimura T, Ochi S, Tsuruta Y, Yamazaki Y. Sustained release 
liquid preparation using so-dium alginate for eradication of Helicobacter pylori. Biol 
Pharm. Bull. 22 (1999) 55–60. 
 
22.Kawashima Y,  Niwa T,  Takeuch H, Hino T, Ito Y. Preparation of multiple unit 
hollow microspheres (microballoons) with acrylic resin containing tranilast and their 
drug release characteristics (in vitro) and floating behavior (invivo), J. Control. Release 
16 (1991) 279–290. 
 
 
 
 
79 
 
 
23. Kumar P, Singh S and Mishra B .Gastroretentive Drug Delivery System of 
Ranitidine Hydrochloride Based on Osmotic Technology: Development and Evaluation 
Current Drug Delivery, (2008), 5, 332-342. 
 
24.Liandong Hu , Li Li, Xun Yang, Wei Liu, Jianxue Yang, Yanhong Jia, Chuang 
Shang, Hongxin Xu Floating matrix dosage form for dextromethorphan hydrobromide 
based on gas forming technique: In vitro and in vivo evaluation in healthy volunteers 
European Journal of Pharmaceutical Sciences 42 (2011) 99–105. 
 
25. Lingam Meka, Bhaskar Kesavan, Venkatasimhadri Naidu Kalamata, Chandra 
Mohan Eaga, Suresh Bandari, Venkateswarlu Vobalaboina, Madhusudan Rao Yamsani 
Design and Evaluation of Polymeric Coated Minitablets as Multiple Unit 
Gastroretentive Floating Drug Delivery Systems for Furosemide Journal Of 
Pharmaceutical Sciences,(2009) Vol. 98, NO. 6. 
 
26. Lui, C.Y.; Amidon, G.L.; Berardi, R.R.; Fleisher,D.; Youngberg, C.; Dressman, J.B. 
Comparison of gastrointestinal pH in dog and humans: implicationson the use of the 
beagle dog as a model for oral absorption in humans. J. Pharm. Sci. (1986), 75,271–
274. 
 
27. Mastiholimath V S, Dandagi P M, Gadad A P, Rashmi M, & Kulkarni A R. In vitro 
and in vivo evaluation of ranitidine hydrochloride ethyl cellulose floating microparticles 
Journal of Microencapsulation, August (2008); 25(5): 307–314. 
 
28.Mididoddi P.K.; Repka M.A. Characterization of hot-melt extruded drug delivery 
systems for onychomycosis. Eur. J. Pharm. Biopharm.,(2007), 66, 95-105. 
 
 
 
80 
 
29.Mojaverian, P.; Chan, K.K.H.; Desai, A.; John, V.Gatrointestinal transit of a solid 
indigestible capsule as measured by radiotelemetry and dualgama scintigraphy. Pharm. 
Res. (1989), 6, 719–724. 
 
30. Oth M, Franz M,  Timmermans M, Moes A. The bilayer floating capsule: a 
stomach-directed drug delivery system for misoprostol,Pharm. Res. 9 (1992) 298–302. 
31.Ozdemir N, Ordu S, Ozkan Y. Studies of floating dosage forms of furosemide: in 
vitro and in vivo evaluation of bilayer tablet formulation. Drug Dev Ind Pharm.( 
2000);26:857-866. 
 
32. Pablo E, Gutiérrez-Sánchez,A, Hernández-León,L, Villafuerte-R. Effect of Sodium 
Bicarbonate on the Properties of Metronidazole Floating Matrix Tablets Drug 
Development and Industrial Pharmacy, 2008 34:171–180. 
 
33. Praneeth Kumar S, Suresh B, Raju J, and Prabhakar Reddy V. Formulation and 
Characterization of Floating Gelucire Matrices of Metoprolol Succinate. Dissolution 
Technologies | AUGUST( 2010). 
 
34. Reshu Gupta and Kamla Pathak Optimization Studies on Floating Multiparticulate 
Gastroretentive Drug Delivery System of Famotidine Drug Development and Industrial 
Pharmacy,(2008) 34:1201–1208. 
 
35. Rouge N, Allemann E, Gex-Fabry M, Balant L, Cole E.T, Buri P, Doelker E.  
Comparative pharmacokinetic study of a floating multiple-unit capsule, a high-density 
multiple-unit capsule and an immediate-release tablet containing 25 mg atenolol.Pharm 
Acta Helv.(1998) 73:81–7. 
 
36. Rubinstein A. Microbially controlled drug delivery to the colon. Biopharm.Drug 
Dispos. (1990), 11, 465–475. 
 
 
81 
 
37. Sandra S, Hendrik M, Karsten M. Characterization of poly(vinyl acetate) based  
floating matrix tablets Journal of Controlled Release 126 (2008) 149–155. 
 
38.Sanjay P. Boldhane and Bhanudas S. Kuchekar Gastroretentive Drug Delivery of 
Metformin Hydrochloride: Formulation and In Vitro Evaluation Using 32 Full Factorial 
Design.Current Drug Delivery, (2009), 6, 477-485. 
 
39. Sasa B, Julijana K, Franc V, Polona V, Bojan Z. Optimisation of floating matrix 
tablets and evaluation of their gastric residence time International Journal of 
Pharmaceutics 195 (2000) 125–135. 
 
40. Sher, P.; Ingavle, G.; Ponratnam, S.; Pawar, A. Low density porous carrier: Drug 
adsorption and release by response surface methodology using different solvents. Int. J. 
Pharm., (2007), 331, 72-83. 
 
41.  Sheth P R, Tossounian T L. Sustained release pharmaceuvivo evaluation of a novel 
gastric retentive formulation tical capsules, US Patent 4 (1978)., 126, 672,       
November 21. 
 
42. Sheth P.R, Tossounian J, The hydrodynamically balanced Kayano,  system (HBSE): 
a novel drug delivery system for oral use,Drug Dev. Ind. Pharm. 10 (1984) 313–339. 
 
43. Shoufeng L, Senshang L, Bruce P, Haresh L, and Yie W. Chien, Effect of 
Formulation Variables on the Floating Properties of Gastric Floating Drug Delivery 
System DRUG Development And Industrial Pharmacy  (2002) Vol. 28, No. 7, pp.    
783–793. 
 
44.  Shweta A, Javed A, Alka A, Roop K. Khar, and Sanjula B. Floating Drug Delivery 
Systems: A Review:AAPS PharmSciTech (2005) 6 (3) Article 47. 
 
 
82 
 
45.  Shyam S, Bhaskar C, Mahadik K R, and Anant P. Preparation and Evaluation of 
Diltiazem Hydrochloride-Gelucire 43/01 Floating Granules Prepared by Melt 
Granulation AAPS PharmSciTech (2004); 5 (3) Article 43. 
 
46. Singh S, Singh J,  Muthu M S, Balasubramaniam J and  Mishra B. Gastroretentive 
Drug Delivery System of  Metoclopramide Hydrochloride Formulation and In vitro 
Evaluation. Current Drug Delivery, (2007), 4, 269-275.  
 
47. Srivastava A K, Saurabh W,  Ridhurkar D, and  Mishra B. Oral Sustained Delivery 
of Atenolol from Floating Matrix Tablets——Formulation and In Vitro 
Evaluation.Drug Development and Industrial Pharmacy, (2005) 31:367–374. 
 
50. Stops  F, Fell  J.T, Collett  J.H,  Martini L.G, Sharma H.L, Smith A.M. The use of 
citric acid to prolong the in vivo gastroretention of a floating dosage form in the fasted 
state. Int. J. Pharm., 2006, 308, 8-13. 
 
51. Talukder R and Fassihi R Gastroretentive Delivery Systems: A Mini Review Drug 
Development And Industrial Pharmacy(2004) Vol. 30, No. 10, 1019–1028. 
 
52. Varis, K.; IHamaki, T.; Harkonen, M.; Samlof,I.M.; Siruala, M. Gastric 
morphology, function, and immunology in first-degree relatives of probandswith 
pernicious anemia and controls. Scand. J. Gastroenterol. (1979), 14 (2), 129–139. 
 
53. Vivek K, Shaswat K, Garima G, Rajendra A, Deepak S, and Giriraj T. 
Gastroretentive dosage forms: A review with special emphasis on floating drug delivery 
systems Drug Delivery, (2011); 18(2): 97–110. 
 
 
 
 
83 
 
54. Yang L, Esharghi J, Fassihi R. A new intra gastric delivery system for the treatment 
of helicobacter pylori associated gastric ulcers: in vitro evaluation. J Control Release. 
(1999);57:215-222. 
 
55. Zeynep A, Anja V, Tamer G, and Andreas Bernkop S. Gastroretentive particles 
formulated with thiomers: development and in vitro evaluation Journal of Drug 
Targeting, (2010); 18(5): 362–372. 
 
 
